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 Summary 
	  
	  
Generally, pathological conditions or altered physiological events are the 
consequences of different mechanisms altering the normal homeostasis.  
Between these events, angiogenesis that is the process that brings to the 
formation of new blood vessels from pre-existing ones, plays a very important 
role. 
The angiogenic process begins with capillary sprouting and culminates in 
formation of a new microcirculatory bed composed of arterioles, capillaries 
and venules. The initiation of angiogenesis consists of at least three 
processes: 1) breakdown of the basement membrane of the existing vessels, 
2) migration of endothelial cells from the existing vessels towards an 
angiogenic stimulus, and 3) proliferation of endothelial cells (Klagsbrun & 
D’Amore, 1991).  
 
Physiological angiogenesis occurs during wound healing, organ 
regeneration, and in the female reproductive system during ovulation, 
menstruation, and the formation of the placenta; however, angiogenesis also 
occurs in pathological processes such as tumour growth, rheumatoid arthritis, 
diabetic retinopathy, and psoriasis.  
 
A switch to the angiogenic phenotype depends on a local change in the 
balance between angiogenic stimulators and inhibitors (Post et al., 2008), 
since this series of events is subject to a tight control played by the 
“angiogenic balance”, i.e. a physiological balance between the stimulatory 
and inhibitory signals for blood vessel growth, tightly controls angiogenesis 
(Folkman, 1995). 
 
Growing evidences suggest that angiogenesis occurs in the development of 
human pathologies affecting the Central Nervous System (CNS) too, 
although its role is controversial. In fact, new vascularisation should be 
protective in post- ischemic brain (Beck et al., 2009), in cerebral stroke (Arai 
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et al., 2009), and in spinal cord injury (Han et al., 2010), where 
oxygen replacement is beneficial for neuronal cell survival in a hypoxic 
region. On the other hand, angiogenesis can be detrimental where 
inflammatory foci exist within the CNS, as in some neurodegenerative 
disorders (Candelario et al., 2009), since new blood supply may promote the 
increase of pro-oxidant, pro-inflammatory, and also pro- angiogenic 
mediators into the brain.  
Among these neurodegenerative conditions, a negative role of angiogenesis 
has been recently described during Alzheimer Disease (Fioravanzo et al., 
2010). In fact, it seems to be clear that, during hyperactivation of astroglial 
cells, where a scenario of “reactive gliosis” is already in progress, the 
formation of new vessels gets the damaged area worse, in relation to the 
increase of pro-oxidant, pro-inflammatory and pro- angiogenic mediators and 
despite the assumption that angiogenesis brings oxygen and nutrients to the 
hypoxic place (Chrystov et al., 2006).  
 
  In the periphery, a different cell type, mast cell, plays similarly to 
astroglia during neurodegeneration in sustaining angiogenic process. 
Actually, several evidences have shown the important role of mast cells in 
supporting angiogenesis (Iuvone et al., 1999), since their critical presence 
near sites of new capillary sprouting is a fundamental event for the new 
vessel formation. In fact, during specific pathological conditions, such as 
inflammatory or allergic diseases, mast cells become activated and allowed 
to degranulate, in releasing a series of pro- angiogenic mediators (VEGF, 
MMPs, TNF- α).  
  
In parallel, a new class of compounds, ALIAmides, (Autacoid Local Injury 
Antagonism Amides) possessing in vitro and in vivo anti- angiogenic 
activities, has been discovered (Aloe et al., 1993). Between these, recently it 
has been reported that Palmitoylethanolamide, ALIAmides’ ancestor, is able 
to inhibit both astroglial and mast cell activation (Scuderi et al., 2011; De 
Filippis et al., 2010).  
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These evidences are the scientific starting point of my Ph.D. thesis, focused 
on studying the modulation of angiogenesis by ALIAmides through the 
control of astroglial and mast cell behaviour and leading, and, as a 
consequence, a modulation of both CNS and peripheral pathological 
inflammatory conditions. 
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EC Endothelial Cell 
eCBs Endocannabinoids 
ECS Endocannabinoid System 
EGF Epidermal Growth Factor 
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ICAM-1 InterCellular Adhesion Molecule-1 
IFN  Interferon  
ILs Interleukins 
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MC Mast Cell 
MITF  Microphthalmia-Associated 
Transcription Factor 
   
MMPs MatrixMetalloProteases 
MTT         3-(4,5-dimethylthiazol-2-yl)-2,5-      
Dipheniltetrazoliumbromide 
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NO       Nitric Oxide  
PBS       Phosphate Buffer Solution  
PDGF      Platelet-Derived Growth Factor 
PEA       Palmitoylethanolamide 
PI3K       Phosphatidyl-Inositol 3 Kinase 
SP       Senile Plaques 
RT-PCR      Reverse Transcriptase- Polymerase 
Chain Reaction  
TGF-α      Transforming Growth Factor-α 
TGF-β      Transforming Growth Factor-β  
TNFR       Tumor Necrosis Factor Receptor 
TNF-α      Tumor Necrosis Factor-α 
VCAM-1      Vascular Cell Adhesion Molecule-1 
VE-cadherins     Vascular Endothelial-cadherins 
VEGF       Vascular Endothelial Growth Factor 
VEGFR      Vascular Endothelial Growth Factor 
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 1. Introduction 
 
1.1. Angiogenesis 
 
1.1.1. Angiogenesis: an overview  
The blood and the lymphatic vascular system penetrate every organ and 
tissue to supply cells with nutrients and oxygen, providing for the circulation 
of fluids and various signalling molecules. The formation of new vessels is a 
process divided in two different manners: vasculogenesis and 
angiogenesis (Ferrara, 2000). 
Vasculogenesis, the development of the blood vascular system, is one of the 
first events in embryogenesis. During early embryonic development, 
mesodermal cells differentiate into hemangioblasts, progenitors of both 
hematopoietic and Endothelial Cells (ECs) giving rise to blood vessels. 
During differentiation, hemangioblasts produce angioblasts and their 
aggregation results in the formation of blood islands.  
The fusion of blood islands results in the appearance of the primary blood 
vascular plexus consisting of fine capillaries formed by ECs. At this stage 
capillaries acquire an arterial or venous character. The stage of 
vasculogenesis is completed together with the formation of the primary 
vascular plexus and all further transformations of the vascular net proceed 
during angiogenesis (Karamysheva, 2008).  
Angiogenesis is the outgrowth of new vessels from pre-existing vasculature. 
It is an essential process during embryogenesis, wound healing and the 
ovarian cycle but it also plays a major role in several pathologic processes 
such as tumor vascularisation, diabetic retinopathy, psoriasis and rheumatoid 
arthritis (Bouïs et al., 2006). In adults, formation and growth of new vessels 
are under strict control.  
These processes are activated only under strictly defined conditions like 
wound healing. Strict regulation of this system and balanced functioning is 
very important for the organism because both excessive formation of blood 
vessels and their insufficient development lead to serious diseases 
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(Karamysheva, 2008). Scientists have studied the process of capillary growth 
since 1939, when Clark and Clark (1953) observed the process in real time 
using intravital microscopy of the microvascular network within rabbit ear 
chamber.  
In the early 1970s Gimbrone and colleagues (1973) first achieved the 
establishment of long-term EC cultures. Subsequently the development of in 
vitro models of capillary network formation contributed to the understanding 
the angiogenic process (Folkman and Haudenschild, 1980). 
 
 
Figure 1.1.1.: Angiogenic process (Folkman and Shing, 1992)  
 
 
1.1.2. Angiogenic Phases 
The angiogenic process starts after different kinds of stimuli. Stimuli known to 
initiate angiogenesis include hypoxia, inflammation and mechanical factors 
such as stress and stretch. These stimuli either directly or indirectly activate 
ECs by initiating the autocrine or paracrine production and release of growth 
factors or cytokines. Angiogenic sprouting of blood vessels occurs in a series 
of events, which can roughly be divided into a destabilisation phase, a 
proliferation and migration phase and a maturation phase. All these steps 
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offer potential points for pro- or anti- angiogenic clinical 
intervention (Milkiewicz et al., 2006). 
 
Vascular permeability, endothelial cell proliferation and migration 
Angiogenesis initiates with vasodilation, a process involving nitric oxide (NO). 
Vascular permeability increases in response to VEGF, thereby allowin 
extravasation of plasma proteins that lay down a provisional scaffold for 
migrating endothelial cells. Ang1, a ligand of the endothelial Tie2 receptor, is 
a natural inhibitor of vascular permeability, tightening pre-existing vessels. 
Endothelial cells need to loosen interendothelial cell contacts and relieve 
periendothelial cell support to migrate from their resident site; so, mature 
vessels need to become destabilized. Ang2, an inhibitor of Tie2 signalling, 
may be involved in detaching smooth muscle cells from the extracellular 
matrix (Maisonpierre et al., 1997; Gale & Yancopoulos, 1999). Proteinases of 
the plasminogen activator, MMP, chymase or heparanase families influence 
angiogenesis by degrading basal membrane and extracellular matrix 
molecules as well as by activating or liberating growth factors (bFGF, VEGF 
and IGF-1) sequestered within the extracellular matrix (Coussens et al. 
1999). MMP-3, MMP-7 and MMP-9 affect angiogenesis in neonatal bones 
(Vu et al., 1998) and tumours (Bajou et al., 1998), whereas TIMP-1, TIMP-3 
or a naturally occurring fragment of MMP-2, by preventing binding of MMP-2 
to αvα3 integrin, may limit the extent of migration and invasion of endothelial 
cells during tumour angiogenesis (Brooks et al., 1998). 
 
Once the path has been cleared, proliferating endothelial cells can migrate to 
distant sites. Ang1 phosphorylates tyrosine in Tie2 and is chemotactic for 
endothelial cells, induces sprouting and potentiates VEGF, but fails to induce 
endothelial proliferation (Suri et al., 1998).  
In contrast to VEGF, Ang1 itself does not initiate endothelial network 
organization, but stabilizes networks initiated by VEGF, presumably by 
stimulating the interaction between endothelial and periendothelial cells. This 
indicates that Ang1 may act at later stages than VEGF (Gale & Yancopoulos, 
1999). Ang2, at least in the presence of VEGF, is also angiogenic. VEGF and 
its receptor VEGFR-2 affect physiological and pathological angiogenesis and 
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are therapeutic targets, although much remains to be learned about the 
involvement of the distinct VEGF isoforms or of the heterodimers of VEGF 
family members. Members of the fibroblast growth factor (bFGF) and platelet-
derived growth factor (PDGF) family are redundant during normal 
development; both affect angiogenesis probably by recruiting mesenchymal 
or inflammatory cells (Zhou et al., 1998; Lindahl et al., 1998).  
TGF- α1 and tumour necrosis factor TNF-α can either stimulate or inhibit 
endothelial growth, and may be involved in tumour dormancy (Gohongi et al., 
1999).  
 
Nitric oxide, a downstream effector of VEGF, TGF α1 and other angiogenic 
factors, is not essential for embryonic vascular development, but affects 
pathological angiogenesis and improves the re-endothelialisation of naked 
vessels (Murohara et al., 1998). 
 A growing list of molecules is being discovered that are angiogenic after 
exogenous administration, but which molecules function as endogenous 
angiogenic factor remain undetermined (Carmeliet, 2000). 
 
A balance of activators and inhibitors controls angiogenic sprouting (Fig. 
1.1.2).  
Angiogenesis inhibitors, suppressing the proliferation or migration of 
endothelial cells, include angiostatin (an internal fragment of plasminogen; 
O’Reilly et al., 1994), endostatin (a fragment of collagen XVIII; O’Reilly et al., 
1997), antithrombin III, interferon- α (IFN-α), leukaemia inhibitory factor (LIF) 
and platelet factor 4 (PF4) (Carmeliet, 2000). 
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Figure 1.1.2.: Angiogenesis: the balance. Illustration of “angiogenic balance”. 
 
 
 
Lumen formation 
Migrating endothelial cells often assemble as solid cords that subsequently 
acquire a lumen. Intercalation or thinning of endothelial cells and fusion of 
pre-existing vessels allow vessels to increase their diameter and length 
(Carmeliet, 2000). Specific VEGF isoforms play distinct roles in this moment, 
i.e. VEGF189 isoform decreases luminal diameter, whereas VEGF121, 
VEGF165 and their receptors increase lumen formation, in addition to 
increasing vessel length. Ang1 in combination with VEGF also increases 
luminal diameter (Suri et al., 1998). Other molecules affecting lumen 
formation are integrins (αvβ3 or α5) and the myocyte enhancer binding factor 
2C (MEF2C) transcription factor. Excessive proteolysis may lead to cystic 
assembly of endothelial cells and prevent tube formation. Thrombospondin 
(TSP)-1 is an endogenous inhibitor of lumen formation (Carmeliet, 2000). 
 
Endothelial survival and differentiation 
Once assembled in new vessels, endothelial cells become quiescent and 
survive for years (Carmeliet et al., 1999). Endothelial apoptosis is a natural 
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mechanism of vessel regression in the retina and ovary after birth and a 
frequent (therapeutic) inhibitor of angiogenesis. Endothelial apoptosis is 
induced through deprivation of nutrients or survival signals when the lumen is 
obstructed by spasms, thrombi or the shedding of dead endothelial cells, or 
when a change in the angiogenic gene profile occurs (Jain et al., 1998; 
Gerber et al., 1999). The survival function of VEGF depends on an 
interaction between VEGFR2, α-catenin and vascular endothelial (VE)-
cadherin (Carmeliet et al., 1999). Ang1 also promotes, whereas Ang2 
suppresses, endothelial survival, at least in the absence of angiogenic stimuli 
(Gale & Yancopoulos, 1999; Holash et al., 1999). 
Haemodynamic forces are essential for vascular maintenance, as 
physiological shear stress reduces endothelial turnover and abrogates TNF-α 
mediated endothelial apoptosis.  
Endothelial apoptosis can be also induced by NO, ROS, angiostatin, TSP-1, 
the metallospondin METH-1, IFN-α, tissue factor pathway inhibitor (TFPI) 
and vascular endothelial growth inhibitor (VEGI) (Carmeliet, 2000). 
To accommodate local physiological requirements, endothelial cells acquire  
specialized characteristics that are determined in part by the host tissue 
(Risau, 1998). For example, an interaction of astroglial cells expressing glial 
fibrillary acidic protein, pericytes and normal angiotensinogen levels is 
essential for development of the blood-brain barrier (Lindahl et al., 1998). In 
contrast, endothelial cells in endocrine glands, involved in the exchange of 
particles, become discontinuous and fenestrated; this is possibly mediated by 
interactions between VEGF and the extracellular matrix. 
 
Remodelling, vessel maturation and stabilisation 
The remodelling of the endothelial network involves the pruning of capillary- 
ike vessels with uniform size, and irregular organization into a structured 
network of branching vessels. Intussusceptions, resulting in replacement of 
vessels by extracellular matrix, underlie pruning and branching (Fig. 1.1.3.). 
Gene inactivation studies indicate a morphogenetic function for VEGF and 
VEGFR- 3 (Carmeliet et al., 1996; Ferrara et al., 1996; Dumont et al., 1998), 
the endothelial receptor Tie1 (Patan, 1998), integrin, fibronectin and others 
(Carmeliet, 2000). 
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The maturation of the neovascular bed is characterised by a 
recruitment of mural cells. Endothelial cells from large vessels recruit smooth 
muscle cells whereas endothelial cells in microvessels recruit pericytes. The 
mural cells stabilise nascent vessels by inhibiting endothelial proliferation and 
migration, and by stimulating production of a new basal membrane and 
extracellular matrix. 
They thereby provide haemostatic control and protect new endothelium-lined 
vessels against rupture or regression. Indeed, vessels regress more easily as 
long as they are not covered by smooth muscle cells (Benjamin et al., 1998). 
PDGF-B secreted by the endothelial cells recruits pericytes and smooth 
muscle cells (Lindahl et al., 1998). VEGF also promotes mural cell 
accumulation, presumably through the release of  DGFB or binding to VEGF 
receptors (Benjamin et al., 1998). 
Ang1, Tie2 and Ephrin- 2 affect growth and maintenance of blood vessels by 
stabilizing the interaction of mural cells with the nascent endothelial channel, 
and by inducing branching and remodelling (Suri et al., 1996; Maisonpierre et 
al., 1997; Gale & Yancopoulos, 1999). 
TGF- α1, TGF- αR2 (Transforming Growth Factor- α Receptor II), endoglin 
(an endothelial TGF-α binding protein) and Smad5 (a downstream TGF-α 
signal) are involved in vessel maturation in a pleiotropic manner: they inhibit 
endothelial cell proliferation and migration, induce smooth muscle 
differentiation and stimulate extracellular matrix production (Dickson et al., 
1995; Li et al., 1999). 
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Figure 1.1.3.: Schematic angiogenic process: the degradation of the ECM 
and vascular basal membrane (VBM) of existing blood vessel, proliferation 
and migration of endothelial cells towards an angiogenic stimuli, and 
formation and maturation of the new blood vessel sprout with the recruitment 
of pericytes are shown. 
 
 
1.1.3. Cell types involved in angiogenesis 
Many cell types are involved in angiogenesis: 
Ø ECs; 
Ø Endothelial Progenitor Cells (EPCs); 
Ø Pericytes and smooth muscle cells; 
Ø Inflammatory cells. 
 
ECs 
ECs are the most quiescent and genetically stable cells of the body. Their 
turnover time is usually hundreds of days in contrast to bone-marrow cells 
which maintain an average turnover time of 5 days. ECs are bound to 
capillary BM which is composed of type IV collagen, laminin, heparin-
sulphate proteoglycans, perlecans, nidogen/entactin, SPARC/BM-
40/osteopontin, type XV collagen, type XVIII collagen and other molecules. 
This indicates that the primary signals originating from capillary BM inhibit 
proliferation and promote an environment that facilitates appropriate cell-cell 
adhesion (Kalluri, 2003). 
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During angiogenesis to prevent the disintegration of the vascular 
network under angiogenic stimulus and the blood supply to tissue in this 
region, just some ECs inside the capillary initiate angiogenesis. These cells 
are called “tip-cells” and occupy the leading position while new vessels grow: 
they react to the VEGF-A gradient that specifies the direction of their 
migration and which induces the capillary to grow towards the gradient 
(Karamysheva, 2008) sprouting phyllopodii towards the VEGF-A gradient 
(Gerhardt et al., 2003). This effect is caused by the interaction of VEGF-A 
with the VEGF receptor (VEGFR2), the concentration of which is high in tip-
cells. Once tip cells are selected to move forward, formation of new 
capillaries should begin because of the proliferation and migration of other 
ECs (Karamysheva, 2008). 
 
EPCs 
The first EPCs were described as CD34-enriched mononuclear cells that 
acquired endothelial surface marker expression in culture (Asahara et al., 
1997). Subsequent studies showed that a subpopulation of circulating CD34+ 
cells expressing CD34+ CD133+ VEGFR2+ could form endothelial colonies 
in vitro (Peichev et al., 2000; Gill et al., 2001). Other studies have shown that 
CD11b+ or CD14+ mononuclear cells give rise to endothelial cell-like 
colonies both in vitro and in vivo. Thus it appears that endothelial- like cells 
can arise from within bone marrow-derived haematopoietic progenitor cell 
populations or monocyte populations (Garmy-Susini and Varner, 2005). 
EPCs cultivated from different sources showed a marked expression of 
growth factors such as VEGF and Hepatocyte Growth Factor (HGF). The 
release of growth factors in turn may influence the classical process of 
angiogenesis, the proliferation and migration as well as survival of the mature 
cell (Fig. 1.1.4.). The capacity of EPCs to physically contribute to vessel-like 
structures may contribute to their potent capacity to improve 
neovascularisation (Urbich and Dimmeler, 2004). 
 
Pericytes and smooth muscle cells 
The maturation of primordial vascular tubes is accompanied by the 
emergence of peri-endothelial cells that participate in matrix formation and 
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that eventually become pericytes (cells locate in the same BM as the ECs) 
or vascular smooth muscle cells (cells locate outside the vascular BM and 
equipped with specific actin-myosin filaments). Recently the transmembrane 
molecule endoglin has been identified as an essential regulator of pericytes 
and vascular smooth muscle cells differentiation that modulate the 
interaction of Transforming Growth Factor β (TGFβ) superfamily members 
and their receptors and even is expressed in vascular smooth muscle cells 
(Kurz, 2000). 
 
Inflammatory cells 
Most components of the immune system are involved in angiogenic 
processes (Fig. 1.1.4.). A disruption of the microenvironment homeostasis 
leads to activation of resident cells as mast cells, resident macrophages and 
dendritic cells (Albini and Sporn, 2007). In particular macrophages are known 
to produce a series of angiogenic factors including VEGF. 
Exposure of macrophages to hypoxia enhances expression of molecules 
related to angiogenesis, as MMP9, MMP12, Tumor Necrosis Factor-α (TNF-
α) and Interleukin-10 (IL-10). In addition to being a source of VEGF 
macrophages are also influenced by this angiogenic factor, modulating their 
biological activity in response to VEGFR1 ligands. 
In the last few years it has become apparent that neutrophils, like 
macrophages, are sensitive to the microenvironmental clues and adjust their 
behaviour in response to the local and distant signals (Noonan et al., 2008). 
They have been shown to play an important role in physiological and 
pathological angiogenesis (Heryanto et al., 2004). Neutrophil dependent 
angiogenesis in vivo has been shown to require VEGF-A release by 
neutrophils upon recruitment and stimulation. In response to stimulation the 
degranulate and release proteases, activate phagocytosis and oxidate burst 
generation before dying. In addition to VEGF-A neutrophils have been shown 
to make a wide range of angiogenesis molecules and an equally wide range 
of anti-tumour and anti- angiogenic molecules (Benelli et al., 2003). The key 
appears to lie within the response of these cells to the signal from the 
microenvironment (Noonan et al., 2008). 
The high levels of VEGF may recruit leukocytes and natural killer cells. ECs 
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exposed to VEGF up-regulate InterCellular Adhesion Molecule-1 
(ICAM-1) expression which play a key role for CD18 mediated neutrophil 
adhesion and recruitment. 
VEGF also induce Vascular Cell Adhesion Molcecule-1 (VCAM-1) expression 
on ECs, which together with ICAM-1 recruit activated natural killer cells. 
Natural killer cells are known as negative regulators of angiogenesis but they 
can also induce angiogenesis by secretion of pro- angiogenic cytokines like 
VEGF, Platelet Growth Factor (PlGF) and Interleukin-8 (IL-8) (Hanna et al., 
2006). 
 
 
Figure 1.1.4.: The sequence of events in acute inflammation and tissue repair. The 
process of inflammation initiates a series of catabolic and anabolic processes that occur in a 
defined order. Firstly the activation of resident cells (mast cells, resident macrophages and 
dendritic cells) and rapid entry of granulocytes in response to injury. Further recruitment of 
macrophages and infiltration of effector immune cells (lymphocytes) to enable ECs and 
fibroblast to form new blood vessels and a collagenous matrix. The last step is tissue 
remodelling (Albini and Sporn, 2007). 
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1.1.4.       Pro- angiogenic factors 
The most known classification of pro- angiogenic factors is about their 
activation. They can be divided in two categories: 
Ø direct factors, when they stimulate EC proliferation or migration 
directly; 
Ø indirect factors, when EC proliferation and/or migration which is 
observed in vitro must have been induced by some other factors or cells, 
perhaps indirectly mobilized by the original angiogenic molecule (Folkman 
and Shing, 1992). 
 Numerous molecules perform critical functions within the complex 
angiogenic cascade. Production and activation of these growth factors, EC 
growth factor receptors and intracellular signalling mediators and 
transcription factors trigger the phases that comprise the abluminal sprouting 
form of angiogenesis (Milkiewicz et al., 2006). Some of the soluble growth 
factors, membrane-bound molecules and mechanical forces that mediate 
angiogenic process are summarized in Table 1. 
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Table 1.: Factors regulating normal angiogenesis. VEGF; uPA, urokinase Plasminogen 
Acti- vator; PAI-1, Plasminogen Activator Inhibitor-1; Ang-1, Angiopoietin-1; Ang-2, 
Angiopoietin-2; vWf, von Willebrand factor; aFGF, Fibroblast Growth Factor a; bFGF, 
Fibroblast Growth Fac- tor b; PDGF, Platelet Derived Growth Factor; VEGFR2, Vascular 
Endothelial Growth Factor Receptor type 2; TGF-β, Transforming Growth Factor β; VSMA, 
Vascular Smooth Muscle Ac- tin; TNF-α, Tumor Necrosis Factor-α; EGF, Epidermal Growth 
Factor; TGF-α, Transforming Growth Factor-α; G-CSF, Granulocyte-Colony Stimulating 
Factor; GM-CSF, Granulo- cyte/Macrophage-Colony Stimulating Factor (Papetti and 
Herman, 2002). 
 
 
 
VEGF family and receptors 
 The VEGF family and its receptors have been known for long to play a 
central and specific role in angiogenesis as they mediate vascular 
permeability, EC proliferation, migration and survival (Bouïs et al., 2006 
Ferrara, 2000). VEGF was originally described as a homodimeric 34-42kDa 
protein that increased vascular permeability in the skin (Fig. 1.1.5.).  It was 
identified by a partial purification from the ascites fluid and cell culture 
supernatants of a guinea-pig hepatocarcinoma cell line and termed Vascular 
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Permeability Factor (VPF). In 1989 Ferrara and Henzel identified a 
growth factor for ECs in conditioned medium from bovine follicular pituitary 
cells and called it VEGF. This was subsequently sequenced and found to be 
identical to VPF (Leung et al., 1989; Keck et al., 1989). 
The VEGF gene family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E and PlGF. These glycoproteins belong to a structural superfamily of 
13 growth factors that includes PDGF. VEGF-A is mainly involved in 
angiogenesis while VEGF-C and VEGF-D are involved in lymphangiogenesis 
(Byrne et al., 2005). 
 
 
Figure 1.1.5.: The endothelial cell surface receptor for members of VEGF family and 
their biological activities. VEGF tyrosine kinase receptors consist of seven extracellular Ig-
like domains (numbered), a transmembrane region and an intracellular tyrosine kinase 
domain interrupted by a kinase-insert sequence. The soluble VEGFR-1 contains only the first 
six Ig-like domains. The neuropilins are isoforms-specific receptors for certain VEGF family 
members. The α1-α2 region has homology to components of the complement system; β1-β2 
shares homology with coagulation factors V and VIII, whereas γ domain contain a MAM 
domain (Meprin/A5-neuropilin/Mu), a protein sequence also found in the metalloprotease 
meprin and receptor phosphatase µ (Robinson & Stringer, 2001). 
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Growth factors of VEGF family exert their biological effect via interaction with 
receptors located on EC membranes. Three receptors have been identified: 
Flt-1 (VEGFR1), KDR/Flk-1 (VEGFR2) and Flt-4 (VEGFR3) (Papetti and 
Herman, 2002). The VEGF receptors are transmembrane proteins with a 
single transmembrane domain. The extracellular region of VEGF receptors is 
formed by seven immunoglobulin-like domains (IG I-VII), whereas the 
intracellular part exhibits tyrosine kinase activity and the tyrosine kinase 
domain in these receptors is separated into two fragments (TK-1 and TK-2) 
by an intekinase insert. All VEGF receptors are highly homologous (Ferrara 
2000; Karamysheva 2008). 
 
 
Figure 1.1.6.: Image of VEGF family and VEGF receptors. 
 
 
VEGF-A is a secreted glycoprotein that assembles into a disulphide-linked 
homodimer. There are at least eight known human isoforms that are the 
result of alternative RNA splicing and termed VEGF121, VEGF145, 
VEGF162, VEGF165, VEGF165B, VEGF183, VEGF189 and VEGF206 
according to their length in amino acid (Bouïs et al., 2006). Functional VEGF 
receptors were originally characterized as EC specific but they have recently 
been found on other normal cell types including vascular smooth muscle cells 
and monocytes/macrophages (Papetti and Herman, 2002).  
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VEGF-A transcription is stimulated by hypoxia as a result of 
Hypoxia Inducible Factor (HIF-1) binding to a Hypoxia Response Element 
(HRE) within the VEGF-A promoter. 
Inflammatory mediators (IL-1α and IL-1β, TGF-β, prostaglandin E2) or 
activation of CycloOXygenase-2 (COX-2) as well, also increase VEGF-A 
production by mechanical forces of shear stress and cell stretch. VEGF 
promotes EC survival through activation of the Phosphatidyl-Inositol 3 Kinase 
(PI3K)/Akt pathway and through association with αvβ3 integrin and activation 
of focal adhesion kinase (Milkiewicz et al., 2006). It may increase EC 
permeability by enhancing the activity of vescicular-vacuolar organelles, 
clustered vesicles in EC lining small vessels that facilitate transport of 
metabolites between luminal and abluminal plasma membranes. 
Alternatively VEGF may enhance permeability by loosening adherens 
junctions between ECs in a monolayer via rearrangement of cadherin/catenin 
com- plexes. Increased vascular permeability may allow for the extravasation 
of plasma proteins and formation of ECM favourable to ECs and stromal cell 
migration. Moreover VEGF stimulates EC production of Plasminogen 
Activator Inhibitor-1 (PAI-1) and interstitial collagenase. Therefore VEGF 
induces a balanced system of proteolysis that can remodel ECM components 
necessary for angiogenesis (Papetti and Herman, 2002). 
 
 
VEGF-B is a growth factor that binds and activates VEGFR1 as well as NRP-
1 (Papetti and Herman, 2002) inducing expression and increased activity of 
PAI-1 suggesting a role in ECM degradation and EC migration (Bouïs et al., 
2006). VEGF-B is mitogenic for ECs and similarly to PlGF may cooperate 
with VEGF through its ability to form heterodimers with VEGF (Papetti and 
Herman, 2002) but it does not appear necessary for angiogenesis as 
demonstrated in mice deficient in VEGF-B that exhibit only minor cardiac 
defects (Aase et al., 2001). 
VEGF-C and VEGF-D (also known as c-Fos Induced Growth Factor, FIGF) 
form a subgroup within the VEGF family as they consist of a central VEGF 
homology domain with N- and C-terminal extensions that are cleaved during 
protein maturation and are not seen in the other VEGFs or PlGF (Bouïs et al., 
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2006). Both VEGF-C and VEGF-D stimulate angiogenesis in vitro and in vivo 
but their physiological roles are still undefined (Papetti and Herman, 2002). 
VEGF-E refers to a group of VEGF-related proteins encoded by the orf virus, 
a parapoxvirus that infects sheep, goats and occasionally humans These 
viral proteins have retained VEGF function because they signal through 
VEGFR-2 ad stimulate angiogenesis in vitro and in vivo (Papetti and 
Hermann, 2002; Byrne et al., 2005).  
 
Angiopoietins (Ang) 
Four Ang have been identified and form a family of secreted proteins, Ang-1, 
Ang-2, Ang-3 and Ang-4 (Fielder and Augustin, 2006), that all bind to 
endothelium-specific receptor tyrosine kinases, the Tyrosine kinase with 
immunoglobulin and epidermal growth factor homology domains 1 and 2 
receptor (Tie1 and Tie2) (Bach et al., 2007). The Tie receptors are almost 
exclusively expressed by ECs and hematopoietic stem cells. Ang and Tie 
receptors play a key role in angiogenesis (Otrock et al., 2007). 
The best characterized are Ang-1 and Ang-2 which are 60% identical. 
 
Ang-1 binds specifically to Tie2 thus activating it by inducing phosphorilation. 
This interaction does not promote the growth of cultured ECs however it 
induces migration, tube formation, spouting and survival (Bach et al., 2007). 
Many different cell types constitutively express ang-1: pericytes, smooth 
muscle cells, fibroblast and some tumor cells (Fielder and Augustin, 2006). In 
adults the Ang-1/Tie2 signalling system is essential for the maturation of 
vessels by maximizing the interaction between ECs and their surrounding 
support cells and matrix and stabilizing vessels (Post et al., 2008). Ang-1 is 
anti-inflammatory, protects against cardiac allograft arteriosclerosis and 
radiation-induced EC damage, promotes wound healing, inhibits VEGF- 
induced blood vessel formation and adhesion molecule expression. On the 
contrary its overexpression induces blood vessel and lymphatic angiogenesis 
(Fiedler and Augustin, 2006). 
Ang-2 is the natural antagonist of Ang-1 by the inhibition of Tie2 
signalling (Post et al., 2008). It is mainly produced by ECs and pericytes 
(Bach et al., 2007). Ang-2 mRNA is induced dramatically at the site of 
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vascular remodelling, promoting vessel destabilization (Bach et al., 
2007), loosening of cell-matrix and cell-cell interaction. This antagonistic 
effect is thought to be a requirement for the sensitivity of ECs to other 
angiogenic factors such as VEGF (Post et al., 2008). Ang-2 up-regulation in 
the absence of other exogenous stimuli might result in vascular 
destabilization and subsequent vessels regression. Diversely to when 
present for a prolonged period or at high concentration, Ang-2 alone induces 
Tie2 phosphorylation in ECs and enhances their angiogenicity. Ang-2 
expression is induced by various cytokines, including VEGF and bFGF and 
by microenvironmental factors (Fielder and Augustin, 2006). The temporal- 
spatial imbalance between the angiopoietins is crucial to the angiogenic 
switch. The presence of a higher level of Ang-2 compared to Ang-1 leads to 
increased angiogenesis and a more aggressive, larger, heavier tumour with a 
higher rate of proliferation that can be highly metastatic. A lower ratio of Ang-
2:Ang-1 gives a slower rate of angiogenesis (Bach et al., 2007).  
Ang-3 and Ang-4 were described as ligands for Tie2 receptor in 1999 
by homology cloning. Ang3 appears to be the mouse equivalent of the 
human protein Ang4. Ang4 has been shown to increase Tie2 phosphorylation 
and induce survival and migration unlike Ang3 that does not produce 
significant changes (Bach et al., 2006). 
 
Fibroblast Growth Factor family (FGFs) 
FGFs are major growth and differentiation factors in embryonic 
development as well as in the adult playing a role in neuronal signalling, 
inflammatory processes, hematopoiesis, angiogenesis, tumor growth and 
invasion. FGFs strongly bind to components of the ECM as HSPG from 
which they can be released by heparin or during ECM breakdown. 
The FGFs binds the receptors FGFR. The two most extensively studied 
members of FGFs are acidic FGF (aFGF or FGF1) and basic FGF (bFGF or 
FGF2). Both aFGF and bFGF induce processes in ECs in vitro that are 
critical to angiogenesis (Papetti and Herman, 2002). bFGF has four known 
alternative splice forms all inducing proliferation, chemotaxis and urokinase 
type plasminogen activator activity, VEGF and VEGFR2 up-regulation in 
ECs, whereas only one isoform is known for aFGF (Bouïs et al., 2006).  
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Platelet-derived growth factor family (PDGF) 
Besides VEGF and FGFs, PDGF has been shown to be one of the most 
potent angiogenesis inducers. Different cell types secrete it: platelets, 
macrophages, ECs, fibroblasts, keratinocytes (Bouïs et al., 2006), myoblasts, 
astrocytes and epithelial cells (Papetti and Herman, 2002). PDGF receptors 
(PDGFR) are made up of complexes between α- and β- subtypes: PDGFRα 
and PDGFRβ. 
PDGFR are transmembrane proteins whose intracellular region 
contains the tyrosine kinase domain separated into two fragments by an 
interkinase insert but the extracellular region of PDGFR is formed by five 
immunoglobulin-like domains (Karamysheva, 2008). The effects of PDGF on 
vascular cells in vitro and in vivo suggest a role for this growth factor 
angiogenesis. Capillary ECs express PDGFRβ and are stimulated by PDGF-
BB not only to increase DNA synthesis but also to form angiogenic chords 
and sprouts in vitro. PDGF also stimulates the proliferation and recruitment of 
cultured smooth muscle cells and pericytes both of which have been shown 
to express PDGFRβ (Papetti and Herman, 2002).  
 
Transforming Growth Factor-β family (TGF-β) 
TGF-β superfamily consists of close to 30 members including TGF-βs 
(TGF- β1, TGF-β2 and TGF-β3), bone morphogenetic proteins, activins and 
inhibins (Holderfield and Huges, 2008).  
TGF-β is expressed by a wide variety of normal and transformed cells. It is 
found in ECM of many tissues. In the microvasculature both ECs and 
pericytes produce TGF-β and possess TGF-β receptors. It can stimulate or 
inhibit cell proliferation, control cell adhesion by regulating production of 
ECM, protease inhibitors and integrins and it can induce cellular 
differentiation. Moreover it regulates expression of a number of genes in 
ECs, particularly those involved in the establishment of, and interaction with, 
the BM (Papetti and Herman, 2002). 
Tumor Necrosis Factor-α (TNF-α) 
TNF is secreted by activated macrophages and activate T lymphocytes 
and it has pleiotropic proprieties between which is the ability to cause 
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apoptosis of tumor- associated ECs that can result in the complete 
destruction of the tumor vasculature. 
TNF is a transmembrane protein, which upon cleavage by the metallopro- 
teinase TACE produces a soluble trimer of 157 amino acid. Both isoforms of 
TNF (membrane and soluble) bind two distinct receptors that are ubiquitous, 
p55 or TNF- R1 and p75 or TNF-R2 (Lejeune et al., 2006). 
Although TNF-α is primarily involved in inflammation and immunity, it shares 
many proprieties with TGF-β, stimulating angiogenesis in vivo and inhibiting 
EC growth (Papetti and Herman, 2002). 
 
Epidermal Growth Factor (EGF) 
EGF is secreted by platelets, macrophages and monocytes and in 
salivary, lacrimal and duodenal glands as well as in the kidney (Bouïs et al., 
2006). EGF binds to the EGF receptor (EGFR) (also known as Human 
Epidermal growth factor Receptor, HER1) or other members of the HER 
family, HER2-4. HER2 signalling induces VEGF production via increases in 
HIFα protein synthesis (Milkiewicz et al., 2006). It has no direct effects on 
vascular endothelium but it is nevertheless involved in tumor proliferation, 
metastasis, apoptosis, angiogenesis and wound healing (Bouïs et al., 2006). 
 
Others soluble growth factors 
Many other soluble factors have been implicated in playing an important 
role in angiogenesis, but their effects on the vasculature are not as 
widespread as the previously discussed factors (Otrock et al., 2007). 
Transforming growth factor-α (TGF-α) binds EGFR. It is a 5 to 6kDa protein 
that is mitogenic for ECs in vitro and induces angiogenesis in vivo. 
Granulocyte Colony Stimulating Factor (G-CSF) and 
granulocyte/macrophage colony-stimulating factor (GM-CSF), proteins 
required for growth and differentiation of hematopoietic precursors, induce 
migration and proliferation of ECs to a limited extend (Papetti and Herman, 
2002). 
Several others soluble substances have been shown to affect angiogenesis.  
Angiogenin induces angiogenesis in the chorioallantoic membrane and 
rabbit cornea assays (Otrock et al., 2007). It binds to extracellular 
  
	   M.	  Cipriano	   	  
	   	  
34 
components and can support the adhesion and spreading of ECs in vitro. It is 
synthesized in small amount in the developing fetus and in large amount in 
the adult (Papetti and Herman, 2002). 
Angiotropin is a polyribonucleopeptide that induces capillary EC mi- 
gration. It is important in triggering the proliferative reactions in wound 
healing by activating microvascular ECs (Otrock et al., 2007). 
 
Integrins 
Integrins are a family of glycosylated, heterodimeric transmembrane 
adhesion receptors involved in cell-cell and cell-ECM interactions (D’Andrea 
et al., 2006). The attachment of ECs to the BM, ECM and each other usually 
occurs in specialised focal contacts where the cytoskeletal actin filaments are 
linked to integrin bound to the ECM through specialised cytoplasmatic 
proteins (Bouïs et al., 2006). They consist of non- covalently associated α- 
and β-subunits. There are 18 α- and 8 β-subunits known that can combine in 
more those 20 different heterodimeric receptors. 
The role of αvβ3 integrin in mediating angiogenesis is evident in the binding 
of ECM components and matrix MMP-2 (Otrock et al., 2007). It is important 
for EC functions in neovascularization and is abundantly expressed on 
angiogenic blood vessels, in granulation tissue but not on vessels from 
normal skin. αvβ3 integrin mediates EC functions in vitro and plays an 
important role in angiogenesis in vivo. Its ligation also suppresses apoptosis 
in ECs, mediating EC survival by promoting proliferation and activation 
(Papetti and Herman, 2002).  
 
Cadherins 
Cadherins comprise a large family of Ca2+-binding transmembrane 
molecules that promote homotypic cell-cell interactions.  
Numerous studies highlighted the importance of VE-cadherin in 
neovascularization. VE-cadherin plays a role in regulating the passage of 
molecules across endothelium (Otrock et al., 2007). Cadherins not only 
establish EC junctional stability in the vessel wall but also enhance EC 
survival by promoting transmission of VEGF antiapoptotic signal to the 
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nucleus, a crucial result necessary for remodelling and maturation 
of vessels in angiogenesis (Papetti and Herman, 2002). 
 
Eph-B4/Ephrin-B2 
A group of RTKs and their ligands, playing a major role in angiogenesis 
are the ephrin (Eph) receptors and their ligands the ephrins.  
Eph receptors belong to the largest known family of receptor tyrosine kinases 
consisting of at least 14 membrane-bound proteins (Papetti and Herman, 
2002): A receptors (EphA1-A8) and B receptors (EphB1-B6) (Bouïs et al., 
2006). Expression of ephrins can be induced by TNF-α and VEGF. They 
promote migration, repulsion, adhesion and attachment to the ECM via 
integrins (Bouïs et al., 2006). Moreover in the nervous system they appear to 
assist axon guidance through repulsive signals and establish borders 
between neuronal compartments (Papetti and Herman, 2002). 
 
Biomechanical forces 
The mechanical forces mediated by blood flow have profound effects on 
vessel growth (Papetti and Herman, 2002). A flowing fluid through a tube 
exerts a force tangential to the tube, called shear stress and another that is 
perpendicular to the tube wall and is caused by the pressure in the vessel, 
called circumferential stretch. Mature vessels can react to both these 
forces. Shear stress from blood flow has been shown to cause changes in 
morphology, cytoskeleton organization, ion channel activation and gene 
expression within ECs in vitro. In these mature systems chronic elevations in 
shear stress lead to increased vessel diameter, whereas chronic increases in 
pressure lead to decreased vessel diameters. This observation has lead to a 
pressure-shear hypothesis, whereby vessels adapt to shear stress as a 
function of local pressure. 
The presence of laminar flow, which is a type of fluid flow where the stream- 
lines of the fluid motion are parallel, has been found to have atheroprotective 
effects on mature blood vessels. Laminar shear stress reduces apoptosis 
and induces antiapoptotic genes, such as Bcl-XL. Moreover it keeps cells 
from proliferating by inhibiting DNA synthesis. The signals that are created by 
flow are sensed through integrins and the cytoskeleton (Jones et al., 2006). 
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Thus microvascular blood vessels are remodelled in angiogenesis through 
several diverse mechanisms. Growth factors secreted from distant cells, 
transmembrane proteins binding to ECM components or to receptors on 
other cells and hemodynamic forces all act in concert to regulate normal 
angiogenesis. In a physiological setting, these factors exert both positive and 
negative influences on blood vessel growth to ensure that angiogenesis is 
confined to metabolic demands of growing and healing tissues (Papetti and 
Herman, 2002). 
 
 
1.1.5.     Endogenous inhibitors of angiogenesis  
Much of the intracellular signalling associated with the angiogenic 
cascade appears to provide positive feedback for the continued activation of 
angiogenesis through their receptors (Bouïs et al., 2006). Some of the 
endogenous inhibitors are reported in Table 2. 
 
Table 2.: Endogenous inhibitors of angiogenesis 
 
 
Angiostatin 
Angiostatin is a fragment of plasminogen and was first determined to 
have anti- angiogenic proprieties because it inhibited neovascularization in a 
mouse tumor model. Angiostatin also inhibit EC proliferation, resulting in 
tumor dormancy through decreased cell replication and increases in 
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apoptosis (Milkiewicz et al., 2006). Several MMPs as well as 
tumor-cell-derived plasmin thiolreductase have been shown to cleave 
plasmin to angiostatin (Bouis et al., 2006). 
 
Endostatin 
Endostatin is a carboxy-terminal fragment of collagen XVIII that was 
shown to specifically inhibit EC proliferation and tumor growth. Endostatin 
inhibits VEGF-induced migration in Human Umbilical Vein ECs (HUVECs). 
Endostatin interferes with VEGF-stimulated VEGFR2 signalling, which may 
occur through direct interaction of endostatin with VEGFR2 (Milkiewicz et al., 
2006). Angiostatin and endostatin has been shown to act synergistically to 
inhibit tumor angiogenesis (Bouis et al., 2006). 
 
Other anti- angiogenic factors 
Anti-thrombin, a plasma proteinase inhibitor of the serpin superfamily, 
is a heparin-binding protein and the major plasma inhibitor of coagulating 
proteases, primarily thrombin and factor Xa. Anti- angiogenic and antitumor 
growth proprieties have been attributes to both the cleaved and the 
uncleaved latent forms of human plasma-derived anti-thrombin (Cao et al., 
2002). 
Interferons (IFNs) have shown a significant anti-tumor activity in pre-clinical 
models and are the most commonly used cytokines in patients. IFNs 
expression precedes the majority of the innate response cytokines and it has 
been proposed to be the first cytokine secreted by antigen-presenting cells 
after antigen stimulation (Minuzzo et al., 2007). 
Vasohibin was described as a gene induced in VEGF-stimulated ECs. The 
gene encodes for a secreted protein that is an inhibitor of tumor 
angiogenesis. The precise mechanism by which vasohibin blocks 
angiogenesis is not yet known, although direct antagonism of growth factor 
receptors has been excluded probably as a negative feedback regulator of 
angiogenesis (Milkiewicz et al., 2006). 
Arrestin, canstatin, restin as well as fragments of prolactin and other 
small fragments could inhibit angiogenesis (Bouïs et al., 2006) 
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1.2. Angiogenesis in specific pathological conditions 
 
1.2.1.        Angiogenesis during Neurodegeneration 
Great emphasis has been addressed to the role of angiogenesis during 
neurodegeneration, a process characterized by neuronal loss in specific 
areas of the central nervous system (Vagnucci and Li, 2003).  
Neurodegenerative diseases are commonly divided into two main groups 
according to phenotypic features: conditions causing problems with 
movements or conditions affecting memory and related to dementia (Kim et 
al., 2009).  
Recent data established that angiogenesis plays a crucial role in the 
evolution of neurodegenerative disorders since it has been demonstrated that 
vascular remodeling occurs during the evolution and the progression of these 
disorders (Fioravanzo et al., 2010). 
The most studied neurodegenerative disorder is Alzheimer’s disease (AD), 
characterized by senile plaques (SPs) of β-amyloid (Aβ) and by 
neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein (Esposito et 
al., 2006).  
A plentiful inflammatory reaction is a common hallmark of several 
neurodegenerative diseases, and it has recently been considered as a pivotal 
mechanism responsible for the progression of the neurodegenerative 
process (Skaper, 2007). 
 Microglia and astrocytes are the resident innate immune cells in the brain 
and produce a plethora of factors, as IL-1, TNF-a, NO, prostaglandins, 
superoxide, which result toxic for neurons (Heneka et al., 2007; Hoozemans 
et al. 2002; for a review, see De Filippis et al., 2009). Behind pro-
inflammatory and pro-oxidant mediators, activated glial cells are able to 
release the whole machinery necessary for the development of the 
angiogenetic process, such as the pro-angiogencic factors VEGF, TNF-α 
together with MMPs, the enzymes degrading extracellular matrix (Tarkowski 
et al., 2002; Thirumangalakudi et al., 2006; Fioravanzo et al., 2010; Fig. 
1.2.1.). 
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Figure 1.2.1.: Image of reactive gliosis. Pro-inflammatory, pro- angiogenic and neurotoxic 
mediators released during reactive gliosis. 
 
 
Even if during neuroinflammation the formation of new vessels brings oxygen 
and nutrients to the injured tissue, several evidences show that this process 
gets worse the reactive gliosis present in the damaged area (Chrystov et al., 
2006). 
Many evidences show the presence of new vessels formation during AD 
(Cantara et al., 2004; Yang et al. 2004). In the intratecal lumen of post 
mortem brain of patients affected by AD, i. e., a significant increase of the 
pro- angiogenic VEGF and TGF-β expression was found (Chiappelli et al., 
2006). Moreover, recent data obtained by histological analysis from the 
hippocampus, midfrontal cortex, substantia nigra pars compacta (SNpc), and 
locus ceruleus of AD patients, reported an increased number and diameter of 
blood vessels, thus confirming the occurrence of angiogenesis in AD. In the 
same study, furthermore, it has been recognized that angiogenic vessels are 
different from patent vessels, not only in diameter, but also in structure, since 
they present numerous fenestrae, widened inter-endothelial junctions, 
abnormal endothelial cell shapes, and abnormal basement membranes 
(Carmeliet et al., 2000). 
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Another confirmation that angiogenesis occurs during neurodegeneration in 
AD brains is that new vessels formation have been found into the Aβ senile 
plaques, too. Besides this, vascular Aβ deposition, also known as cerebral 
amyloid angiopathy, is associated with vascular dysfunction in animal and 
human studies. Finally, AD is related with morphological changes in capillary 
networks, and soluble Aβ produces abnormal vascular responses to 
physiological and pharmacological stimuli. This last evidence is emphasized 
by the role of hypoxic transcription factor-1a (HIF-1a), regulator of hypoxia in 
AD, that seems to increase the expression of beta-secretase (BACE), 
bringing about the proteolytic cleavage of the Aβ precursor protein (APP) in 
Aβ peptide (Zhang and Xu, 2007). Moreover, the same HIF-1a, that is up-
regulated in a hypoxic cell, is able to activate the transcription of VEGF; 
subsequently, VEGF binds VEGFR on the capillary surface and leads to a 
key- series of events: the change of vessel permeability, the activation of 
endothelial cells which start to proliferate and to release mediators able to 
break down the basement membrane and, finally, the activation of MMPs, 
that cleave the surrounding extracellular matrix, allowing the endothelial cells 
to migrate leading to  tube formation (Qutub et al., 2009). 
Furthermore, a recent post-mortem study indicated that brain regions 
affected by AD pathology (i.e., hippocampus, midfrontal cortex, substantia 
nigra, and locus ceruleus) are sites of active angiogenesis. In particular, in 
the hippocampus, the on-going angiogenesis resulted in increased vascular 
density, that directly correlated with Aβ load, suggesting that angiogenesis in 
AD and may be related to tissue injury (Desai et al., 2009; for a review, see 
De Filippis et al., 2010). 
These results are confirmed not only by several experimental studies 
indicating that the injection of pro- angiogenic mediators in normal brain 
induces AD-related symptom and signs, but also by other evidences on 
animal models of AD, which are habitually accompanied with important 
vasculature changes (Esiri, 2000).  
In view of all these evidences, to underline the correlation between new 
vessel formation and AD and its possible pharmacological modulation still 
remains very important for the progression of this disease. 
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1.2.2. Angiogenesis during Inflammation 
The signals controlling angiogenesis, while directed at the endothelial cells, 
come from cells in the nearby tissues (Folkman and Brem, 1992). As 
previously described, different cells are able to produce angiogenic factors 
when the environment becomes hypoxic or inflammatory, including tumor 
cells, keratinocytes, monocytes, macrophage and mast cells. Of all these 
cells, the inflammatory monocyte- macrophage-mast cell type can be found 
at most sites where angiogenesis is occurring in an abnormal environment, 
including wound healing and disease (De Filippis et al., 2008). Activated 
monocytes and/or macrophages alone are sufficient to induce angiogenesis 
in the avascular cornea (Koch et al. 1996). In fact, almost every growth factor 
and cytokine known to regulate angiogenesis can be produced by 
macrophages (Sunderkotter et al., 1994). 
Factor capable of inducing angiogenesis are categorized as either indirect, 
those that act via intermediary mechanisms, often being found to induce 
angiogenesis only in vivo, or direct, those also able to induce proliferation, 
migration, and/or differentiation of endothelial cells directly in vitro.   
Obviously, as well explicated in the first paragraph, VEGF appears to be the 
most endothelial cell proliferation and migration; in vivo, it is potently 
angiogenic and causes vascular permeability. Together with VEGF, after 
adamage, other factors released by inflammatory cells have direct or indirect 
effects on endothelial cells, including TGF-α, TGF-β PDGF (Sunderkotter et 
al., 1994). During chronic inflammation, i.e, several pro- angiogenic 
mediators are implicated, since angiogenesis occurs for the maintenance of 
tissue perfusion, in allowing the increase in cellular trafficking necessary for 
chronicity (De Filippis et al. 2008). 
 In granulomatous tissue, a chronic inflammation, for example, nitric oxide 
produced by the endothelium and macrophages by inducible NO synthase is 
an important mediator of tissue destruction and oedema in inflammation 
(Iuvone et al., 1994; Appleton et al., 1996). Granuloma is a specific well- 
characterized experimental procedure during which there is a strong 
implication of pro- angiogenic and pro-inflammatory factors (Iuvone et al., 
1994; Iuvone et al., 1999).  
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In fact, it is characterized by the formation of a specific tissue that includes an 
intense angiogenesis and infiltration of inflammatory cells (Lage and 
Andrade, 2000). Granulomatous tissue is histologically characterized by the 
presence of infiltrating macrophages, epithelioid and giant cells, activated 
mast cells (Forehand and Johnston, 1995) 
Among the cells participating in granuloma formation, connective MCs, 
especially present in the skin, importantly contribute to the development of 
chronic inflammation. MCs, shown to be in a large part near sites of new 
capillary sprouting, are implicated in angiogenesis; in fact they produce, store 
and release several mediators, both vasoactive amines (Metcalfe et al., 
1997) and several enzymes degrading the connective tissue matrix, in 
providing new space for neovascular sprouts  
The implication of these cells and of their releasing factors give to the 
granulomatous chronic inflammation an important explicative role to 
characterize angiogenic process. 
 
 
1.2.3. Angiogenesis during Dermatitis 
Several evidences show that there is a strong implication between 
angiogenesis and dermatitis. Dermatitis is most commonly defined as an 
inflammation of the skin. Symptoms of dermatitis include red, swollen, itchy 
and/or blistered skin. There are two basic types of dermatitis: endogenous 
(“from within”) dermatitis is an often-chronic allergic skin condition that has no 
apparent external cause; exogenous dermatitis, also known as contact 
dermatitis has recognisable external causes.  
The evidence of a presence of new vessel formation during dermatitis, is well 
reported in particular during contact allergic and atopic dermatitis, since the 
participation of a specific immunity cell, in particular mast cells, able to 
release different kinds of pro- angiogenic factors, is testified in literature 
(Groneberg at al., 2005). 
Between these types of dermatitis, contact allergic dermatitis (CAD) is a 
specific one defined as a delayed hypersensitivity reaction that occurs after 
repeated exposure to an allergen.  
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Numerous irritants and/or allergens (nickel, rubber, plants, 
medications) can induce CAD, and the corresponding rash develops within 
48–72 hs of re-exposure to the same antigen. Additional symptoms are 
itching, redness, swelling and the formation of small skin blisters. CAD 
develops in two steps: (1) contact of an allergen with the skin and its binding 
to Langerhans cells, which then travel to lymphnodes, where the allergen is 
exposed to T-lymphocytes; the allergen is also taken up by resident and 
newly recruited dendritic cells, which migrate to lymph nodes and prime the 
T-lymphocytes; and (2) re-exposure to the allergen, which causes the 
activation of primed T-lymphocytes, with subsequent release of inflammatory 
mediators that are responsible for the features of inflammation and 
keratinocyte injury (Karsak et al., 2007; Imada et al., 2002). 
In a mice model of 21 days- DNFB induced CAD, explained by Karsak et al., 
i.e, it has been well-characterized the presence of activated keratinocytes 
during the early phase of the disease (Petrosino et. al., 2011), while a strong 
involvement of another different cell type, mast cells, it has been shown 
during the final phase, as it normally happens during other similar types of 
dermatitis. Mast cells, once activated, are able to release different types of 
mediators, between which pro- angiogenic mediators. 
In parallel, during the last phase of CAD, it has been described the presence 
of small calibre vessels, as a proof of on-going angiogenesis.  
Therefore, the modulation of mast cell activation results a momentous 
approach to regulate mast cell sustained angiogenesis during CAD. 
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1.3.     Mast Cells 
 
1.3.1.     Mast cells during angiogenesis and inflammation 
In 1879 Paul Ehrlich firstly described mast cells.  
Initially, in rodents, MCs were divided into two subtypes depending on the 
variable content of the neutral serine proteases, tryptase and chymase. Thus, 
MCs containing only tryptase represent the mucosal MCs, preferentially 
localised in the mucosa of the airways and gastrointestinal tract. MCs 
containing chymase, tryptase, carbossipeptidase and chatepsin G are 
defined as connective-tissue MCs, which are typically found in the skin, 
synovium, peritoneum and peri-vascular tissues. However, in other species, 
including humans, another subtype has been identified containing chymase 
and carbossipeptidase and possessing a different tissue localisation 
(Bradding et al., 1995). 
Their strategic localisation that directly interfaces with the external 
environment makes MCs acting as surveillance antennae against different 
types of injury and, whenever necessary, they can activate and regulate both 
innate and adaptive immune mechanisms (Bienenstock et al., 1986). 
Moreover, MCs possess important physiological roles that support 
homeostatic control, such as in tissue remodelling, wound healing, and the 
neuroimmune response to stress (for a review, see Bradding et al., 1995) and 
are located in close proximity to blood and lymphatic vessels (Sacchi et al., 
2003) and nerves (Newson et al., 1983) in order to perform this function. 
MCs possess several biological mediators that are released from cytoplasmic 
granules primarily due to stimulus-induced degranulation; including 
vasoactive amines such as histamine, proteoglycans (mainly heparin and 
chondroitin sulphate), neutral serine proteases, such as tryptase and 
chymase, cytokines and growth factors such as vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor, NGF, transforming growth factor 
(TGF)-β and tumour necrosis factor alpha (TNF-α) (Bradding et al, 1995). 
However, activated MCs can also induce de novo synthesis of several 
inducible enzymes, such as inducible nitric oxide synthase (NOS) or cyclo-
oxygenase-2 (and their products nitric oxide, prostaglandins and 
leukotrienes), together with a plethora of chemokines and cytokines, TNF-a, 
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IL-1a, IL-1b, IL-6, IL-9, IL-12, IL-18 and TGF-b, which function to 
amplify the inflammatory ⁄ immune reaction. Hence, MCs have long been 
known to participate in the inflammatory process and this knowledge was 
based on the evidence that MCs are present and recruited to all inflammatory 
sites. 
 
Figure 1.3.1.: Mast cells activation. Realising of preformed and/or new synthesis mediators 
 
Recently, it became clear that MCs play an important role in orchestrating the 
whole inflammatory process from initiation events to chronic activation. MCs 
are the first immune cells to considerably stimulate the inflammatory process 
due to a rapid release of pro-inflammatory and vasoactive mediators. In 
particular, histamine, cytokines and proteases facilitate a pro-inflammatory 
microvascular environment due to increased vasodilatation, increased 
vascular permeability and local oedema formation, thus increasing the tissue 
delivery of other pro-inflammatory cells (Fig. 1.3.1.) 
Moreover, histamine and TNF-a, released by MCs, increase inflammatory 
cell recruitment due to an increase in (i) endothelial adhesion molecules 
expression (selectin and integrins), and thus the stimulation of leucocyte 
endothelial adhesion and rolling, and (ii) MC-derived leukotrienes and IL-8, 
which act as chemotactic signals for eosinophils, neutrophils and basophils 
(Ribeiro et al., 1997). Therefore, even if the main goal of MC activation is to 
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initiate the inflammatory response to maintain internal homeostasis, 
excessive MC activation could lead to unwanted chronic inflammation. 
Previous studies demonstrate the role of MCs in the chronic inflammatory 
process, showing that granuloma formation in rats was accompanied by 
massive mast cell degranulation, whereas the depletion of MC granule 
contents reduced granulomatous tissue formation by more than 50% (Russo 
et al., 2005; Fig. 1.3.2.).  
    The important role of MCs in chronic inflammation is also linked to their 
fundamental role in angiogenesis. In fact, they are considered dues ex 
machine during new vessel formation, since they are localised in tight contact 
with blood vessels, where they release the main vasoactive compound, such 
as VEGF, TNF-α, together with important extracellular matrix degrading 
enzymes, as metalloproteinases (MMPs) and chymase.  
 
 
Figure 1.3.2.: Mast cell sustaining angiogenesis. Mast cells are able to regulate 
angiogenesis   through the release of pro- angiogenic mediators 
 
Chymase is a peptidase with chymotrypsin-like activity, almost selectively 
expressed by MCs. Together with fibronectin and collagen, chymase directly 
contributes to extracellular matrix degradation, and, indirectly, it plays also an 
important role in the activation of MMPs. 
Thanks to chymase, MCs possess the complete angiogenesis “package”: 
they secrete MMPs, and they can activate and inhibit them, in promoting the 
matrix degradation and, at the same time, in realising several factors which 
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activate endothelial cells. Within chymases family, rat mast cell 
protease-5 (rMCP-5) is the most studied and the most known. 
 
 
1.3.2.   Rat Mast Cell Protease-5 and Microphthalmia-associated   
Transcription Factor 
Rat mast cell protease-5 belongs to a family of serine proteases classified as 
chymases. The chymase family can be further subdivided into two groups: α- 
and β-chymases (Sanker et al., 1997). Among rodent α-chymases, rMCP-5 is 
predominantly expressed in connective tissue type mast cells (MCs) and also 
early in MC development (McNeil et al., 1991). 
Like other MC chymases, rMCP-5 is packed in the MC secretory granules 
intimately bound to proteoglycans and it is released, together with several 
other stored mediators, upon activation (Forsberg et al., 1999). Several 
evidences show that rMCP-5 plays a crucial role in the inflammatory/immune 
process. 
My research group has previously demonstrated that rMCP-5 exhibits pro-
inflammatory and pro- angiogenic effects in rat λ-carrageenin-induced 
granuloma, i.e., a model of chronic inflammation actively sustained by mast 
cell activation (Russo et al., 2005). 
It is also known that MC chymase plays an important role in the allergen-
induced biphasic skin reaction (Tomimori et al., 2002) and in 
eliciting/maintaining cutaneous inflammation in atopic dermatitis (Badertscher  
et al., 2005).  
Moreover, MC chymase has been proposed to increase vascular 
permeability both in skin disease and brain edema during intracerebral 
hemorrhage (He and Walls, 1998; Strbian et al., 2009). 
At a cellular level, MC chymase has been shown to induce the release of 
neutrophil chemoattractants by eosinophils and to mediate interaction 
between MCs and eosinophils in allergic diseases (Terakawa et al., 2006;). 
An appealing pharmacological strategy for controlling rMCP-5 is offered by 
the modulation of its transcriptional pathway. In fact, it has been 
demonstrated that several mouse MCPs (mMCP) are under the 
transcriptional control of Microphthalmia-associated Transcription Factor 
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(MITF) and that, more particularly, mMCP-5 gene expression appears to be 
regulated by a MITF-mediated mechanism (Levy et al., 2006)  
 
MITF belongs to Myc supergene family of basic helix-loop-helix leucine 
zipper (bHLH-Zip) DNA-binding protein; these proteins are dimeric 
transcription factors and important regulators of cell development and 
survival (Hershey and Fisher, 2004). MITF protein is predominantly 
expressed in MCs, melanocytes, heart and skeletal muscles. MITF regulates 
the transcription of a spectrum of genes in MCs, many of which are crucial for 
their differentiation and survival, including several MCPs, protease inhibitors, 
adhesion molecules, metabolic enzyme and growth factor receptors 
(Kitamura et al., 2006). 
 
Phosphorylation/dephosphorylation of proteins is a key-regulatory step in 
protein-protein interactions (Sonnenblick et al., 2004.). MITF takes part to the 
coordinated expression of its target genes through its association with 
different proteins, as a result of protein kinase-dependent phosphorylation 
(Shibahara et al., 2001). Three serine sites (Ser73, Ser298 and Ser409) for 
MITF phosphorylation have been reported (Wu et al., 2000); the 
phosphorylation of these serine sites positively correlates with the up-
regulation of MITF transcriptional activity and degradation of MITF (Fig. 
1.3.3.). In particular the phosphorylation of Ser73 is due to the activation of 
ERK pathway (Hamesath et al., 2008) 
 
Thus, the phosphorylation/dephosphorylation of MITF plays an important role 
in regulating MCs proliferation and the relative expression of their mediators. 
Hence, these evidences suggest a strong correlation between MITF, MCs 
and their stored mediators (chymase in primis) and inflammation. 
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Figure 1.3.3.: MITF. Mechanism of activation/ de-activation of MITF. 
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2.  ALIAmides: Palmitoylethanolamide & Congeners  
 
 
 2.1.   ALIA hypothesis 
The acronym ALIA (Autacoid Local Inflammation Antagonism) was 
formulated when Aloe et al. (1993), when he indicated that some 
endogenous N-acylethanolamines exerted a local antagonism on 
inflammation (Fig. 2.1.1.). 
Rita Levi-Montalcini and co-workers (1996) modified the acronym into 
Autacoid Local Injury Antagonism, in order to explain the mechanism of 
action of Palmitoylethanolamide (PEA) and related fatty acid amides. This 
change was made following the observation that the pharmacological 
effects of PEA appear to reflect the consequences of supplying the tissue 
with a sufficient quantity of its physiological regulators of cellular 
homeostasis (Levi-Montalcini et al., 1996). The effect was first attributed to 
mast-cell activity control. Concomitantly, Mazzari et al. (1996) demonstrated 
that the in vivo anti-inflammatory effects of PEA were due to down-
regulation of mast-cell degranulation.  
Similar results have recently been obtained in dogs and cats. In fact, 
densitometric analysis performed on skin biopsies from cats with 
eosinophilic granuloma complex and treated with PEA, revealed an 
increase in the granular density of cutaneous mast-cells, thereby 
suggesting a decrease in mast-cell degranulation (Scarampella et al., 
2001).  
Using similar techniques, an inhibitory control over mast-cell degranulation 
has been demonstrated in dogs locally exposed to PEA analogues.  
 
Together with PEA, other compounds acting as ALIAmide has been 
described; however, starting from these evidences, Palmitoylethanolamide 
is considered as the early ALIAmide. 
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Figure 2.1.1.: ALIA mechanism 
 
 
 
2.2.     Palmitoylethanolamide 
The endogenous fatty acid amide palmitoylethanolamide (PEA), chemical 
structure N-(2-hydroxyethyl) esadecanamide (Fig. 2.2.1.) is naturally present 
both in animal and in vegetable tissues and is able to enhance both the 
cannabinoid and vanilloid signalling was initially considered as an autacoid, 
acting mainly as an anti-inflammatory agent through the down-regulation of 
mediator release from mast-cells, monocytes and macrophages (Aloe et al., 
1993, Facci et al., 1995; Mazzari et al., 1996; Ross et al., 2000; Scarampella 
et al., 2001).  
In addition to the hypothesis that PEA has potent immunoregulatory 
properties, recent data have demonstrated that PEA may also play a key role 
in the regulation of complex systems involved in the inflammatory response, 
pruritus, neurogenic and neuropathic pain (Di Marzo et al., 2001).   
In general, PEA is thought to be involved in endogenous protective 
mechanisms that are activated in the body as a result of different types of 
tissue damage or stimulation of inflammatory responses and nociceptive 
fibres. 
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Figure 2.2.1.: Palmitoylethanolamide structure. N-(2-hydroxyethyl) esadecanamide 
 
 
 PEA and related fatty acids amides are classified on the basis of their mode 
of action as endocannabinoids and cannabimimetics (Petrosino et al., 2010).  
There is a great deal of evidence showing that PEA may act both as an anti-
inflammatory and anti-nociceptive agent (De Filippis et al., 2011; Lambert et 
al., 2002). However, the real mechanism of action of this endogenous 
compound that mediates its anti-inflammatory, analgesic and anti-pruritic 
effects is still debated. There are at least three hypotheses, supported by 
experimental evidence concerning PEA pharmacodynamics, all seemingly 
different, but for several aspects they may be considered complementary and 
synergistic. 
 
 
2.2.1.       Biosynthesis and inactivation. 
Unlike classical neurotransmitters and hormones which are stored in and 
relased from intracellular secretory vesicles, the production of FAE occurs 
through on-demand synthesis within the lipid bilayer (Cadas et al., 1996; 
Schmid et al., 1990). In mammalian tissues, two concerted and independent 
biochemical reactions are responsible (Fig. 2.2.2.). 
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                                  Figure 2.2.2.:  PEA biosynthesis and inactivation 
 
 
 
The first is the transfer of a fatty acid from membrane-bound phospholipids 
to phosphatidylethanolamine (PE), catalyzed by a calcium ion and cyclic- 
AMP regulated N-acyltransferase (NAT), to form the FAE precursor N-acyl 
phosphatidylethanolamine (NAPE).  
Different FAE precursors are generated according to which fatty acid is 
initially transferred to PE (i.e., the initial transfer of palmitic acid will yield a 
PEA precursor, while that of arachidonic acid will yield an anandamide 
precursor). The second step in FAE synthesis is the cleavage of 
membrane-bound NAPE to release free PEA, which is mediated by a 
NAPE-specific phospholipase D (PLD). This lipid hydrolase shares little 
sequence homology to other members of the PLD family and recognizes 
multiple NAPE species, producing PEA along with other FAEs (Okamoto et 
al., 2004). 
 
 15 
 
 
Fig. 4. PEA biosynthesis and inactivation. The biosynthesis of PEA occurs in a two steps. (1) 
The calcium- and cAMP-dependent transfer of palmitic acid from phosphatidylcholine (PC) to 
phosphatidylethanolamine (PE) to form N-acylphosphatidylethanolamine (NAPE). (2) The 
cleavage of NAPE to release PEA, mediated by a NAPE-specific phospholipase D (PLD). (3) 
PEA is hydrolyzed by fatty acid amide amidohydrolase (FAAH) or PEA-preferring acid amidase 
(PAA) to form p lmitic acid and ethanolamine. 
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Alternatively, a separate mechanism of synthesis has been proposed 
involving a similar two-step reaction: (1) the hydrolysis of NAPE to N- 
palmitoyl-lysoPE (lyso-NAPE) by soluble phospholipase A2 (sPLA2) and (2) 
the subsequent cleavage of lyso-NAPE by a lysophospholipase D (lyso- 
PLD) (Natarajan et al., 1984). The activities of these two enzymes are 
highest in the stomach, brain, and testis (Sun et al., 2004). The relative 
contribution of each of these synthetic pathways is unknown at present. 
PEA inactivation primarily consists of its intracellular hydrolysis by lipid 
hydrolases (Fig. 2.2.2.) (Schmid et al.,1985). One of these enzymes, called 
fatty acid amide hydrolase (FAAH), has been molecularly cloned (Cravatt et 
al., 1996) and extensively characterized (Bracey et al., 2002), and selective 
inhibitors that block its activity in vivo have been developed (Kathuria et al., 
2003). 
A second enzyme, referred to as PEA-preferring acid amidase (PAA), has 
also been identified (Ueda et al., 2001). FAAH, a membrane-bound 
intracellular serine hydrolase, for which PEA is an excellent substrate 
(Désarnaud et al., 1995; Hillard et al., 1995; Ueda et al., 1995; Fowler et al., 
2001), is present in all mammalian tissues, but is particularly abundant in 
brain and liver (Cravatt and Lichtman, 2002). 
In fact, mice lacking the faah gene have dramatically reduced PEA 
hydrolysis and increased PEA levels in brain and liver tissues (Cravatt et 
al., 2004; Lichtman et al., 2002). In contrast to FAAH, PAA activity is most 
abundant in the rodent intestine, spleen, and lung (Ueda et al., 2001). PAA 
recognizes all FAEs, suggesting that it may play a broad role in the 
deactivation of these compounds by intact cells; however, in the presence 
of detergent, this activity displays a marked preference for PEA as a 
substrate (Ueda et al., 2001). 
 
 
2.2.2.        Hypothesis of action 
The molecular mechanism of action of PEA is still controversial and several 
hypotheses have been put forward to explain its anti-inflammatory and 
analgesic effects. These hypotheses include the following:  
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i. an Autacoid Local Injury Antagonism through which PEA 
acts by down- regulating mast-cell degranulation (Aloe et al., 
1993); 
ii. the direct stimulation of the cannabinoid CB2 receptor or of an as-
yet uncharacterized CB2-like receptor, as suggested by results 
obtained in different in vivo studies using the CB2 antagonist 
SR144528;  
iii. an ‘entourage effect’ (Smart et al., 2002) through which PEA acts 
by enhancing the anti-inflammatory and anti-nociceptive effects 
exerted by another fatty acid ethanolamide, anandamide (AEA), 
which is often produced together with PEA. AEA acts by 
activating the cannabinoid CB1 and CB2 or the transient receptor 
potential vanilloid receptor type 1 (TRPV1) channel, and PEA 
might potentiate these actions either via inhibition of the 
expression of FAAH (LoVerme et al., 2005) for which AEA is also 
a substrate, or through allosteric stimulation of TRPV1 receptors, 
or both. Activation of TRPV1 receptors is then immediately 
followed by their desensitization and refractoriness to subsequent 
stimulation by inflammatory or nociceptive stimuli; 
iv. a binding to the orphan G-protein coupled receptor (GPR55), that 
is not yet well-clarified; 
v. last, a specific molecular target has been found for PEA, the 
nuclear peroxisome proliferator- activated receptor-a (PPAR-a), 
which clearly mediates several anti-inflammatory effects of this 
compound (D’Agostino et al., 2007; Scuderi et al., 2011)  
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2.3.   PEA Congeners 
 
2.3.1. Adelmidrol and Fumidrol 
Recent studies have shown the existence of other molecules, classified as 
ALIAmide, able to acts as anti-inflammatory compounds, following the most 
considered exemple of PEA: Adelmidrol and Fumidrol. Adelmidrol is a 
synthetic derivate of azelaic acid, a naturally occurring saturated 
dicarboxylic acid, that is found in some whole grains and intrace amounts in 
the human body (Bonner et al., 1999), its plasma levels normally ranging 
from 20 to 80 ng/mL, while Fumidrol is a synthetic derivate of fumaric acid. 
Between Adelmidrol and Fumidrol, the most studied, according to their 
pharmacological activity, is Adelmidrol. 
Adelmidrol is an amphiphilic or amphipathic compound, possessing both 
hydrophilic and hydrophobic properties, that favour its solubility both in 
aqueous and organic media. The effect of Adelmidrol has been shown to 
depend, at least in part, on the control of MCs granular density, in 
suggesting a decrease in their degranulation (De Filippis et al., 2009). 
In particular, the topical application of a gel formulation containing the fatty 
acid amide Adelmidrol produced a significant increase in the densitometric 
measurement for cutaneous mast-cells located in the lips of dogs with 
experimentally induced wounds. In the dog, the percentage surface re-
epithelialisation associated with the increase in mast-cell densitometric 
measurement was significantly higher in the lesions exposed to aldemidrol 
than in those treated with vehicle.  
Finally, De Filippis et al. (2009), have shown strong anti-inflammatory and 
anti- angiogenic activities of Adelmidrol during granuloma, a specific chronic 
inflammation sustained by mast cell activation in rats, as a proof of its 
potent action in controlling mast cells behaviour.  
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  3. Material and Methods
 
3.1.    Cell Cultures  
 
3.1.1.   C6 Rat Glioma Cell Cultures 
C6 rat glioma cells (ATCC CCL-107) were cultured in 10 cm i.d. Petri dishes 
(3x103/dish) and in 24 multiwells plates (6.25x104/cm2), in Dulbecco's 
modified Eagle's medium supplemented with 5% FBS (fetal bovine serum), 
2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in 
5% CO2, 95% air. 
Confluent cells were treated with 1 µg/ml Aβ 1-42 (Tocris, Ellisville, MO) in 
the presence or absence of the following substances: PEA 10-8-10-6 M 
(Epitech Group, Italy) and the selective PPAR-?antagonist GW6471 (2,5-
10µM) (Tocris, Ellisville, MO). After 48 hours incubation time, cells in Petri 
dishes were subjected to the different treatments, as described below. 
Media of cells in 24 multiwells were collected and used to stimulate HUVEC 
cells. 
 
 
Figure 3.1.1.: Images of C6 cells.  C6 cells in (A) normal conditions and (B) after Aβ-insult. 
 
 
3.1.2.   Human Umbilical Vein Endothelial Cells 
Clonetics® HUVEC Cells (Lonza, Basel, CH) were cultured in Clonetics® 
EGM® Endothelial Growth Medium (Lonza Basel, CH) at 37°C, 5% (v/v) 
 (A)                           (B) 
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CO2. Confluent cells were seeded in 96 multiwells plates (3.125x104/cm2) 
and incubated for 24 hours. After this period of incubation, they were treated 
with supernatant-media of C6 pre-treated cells, and incubated for 48 hours. 
16 hours before the end of incubation time, BrdU was added to evaluate cell 
proliferation.  
 
 
Figure 3.1.2.: Image of HUVEC cells. 
 
 
3.1.3.   Cell Functionality Assay 
To determinate cells functionality, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-Formazan Assay (MTT assay) was performed. Cells 
were plated at the density of 1×105 cells/well, left to adhere for 2 h at 37 °C, 
and then treated as described previously. After 48-h incubation time, 25µl of 
5g/L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium solution were added 
to the cells. Cells were incubated for an additional 3 h at 37 °C before being 
lysed, and then dark blue crystals were solubilized with 125 µl of a 50% N,N-
dimethyl formamide/20% sodium dodecyl sulfate solution with an adjusted pH 
of 4.5. Optical density (OD) was measured with a spectrophotometer 
(Titertek Multiskan MCC/340; Titertek Instruments, Huntsville, AL) equipped 
with a 620-nm filter. Cell viability was calculated as OD treated/OD control 
ratio.  
 
 3.1.4.   Cell Proliferation Assay 
To determine the effect of treatment of C6 cells on HUVEC cellular 
proliferation, Cell Proliferation ELISA BrdU assay (Roche Applied Science, 
  
	   M.	  Cipriano	   	  
	   	  
59 
Monza, Italy) was used. The assay is based on the measurement 
of BrdU incorporation during DNA synthesis. Cells were seeded (3.125x104 
cells/cm2) in 96 wells plates and cultured for 24 hours. The medium was 
removed and C6 media in absence or in presence of Aβ 1-42 1 µg/mL 
(Tocris, Ellisville, MO), PEA (10-8; 10-7; 10-6 M) and the selective PPAR-
?antagonist GW6471 (2,5µM; 5µM; 10µM), were added for 48 hours. Two 
controls were performed: 
1. blank: has to be performed in each experimental setup. The blank provides 
information about the unspecific binding of BrdU and anti-BrdU- POD 
conjugate to the plate. The absorbance value obtained in this control has to 
be subtracted from all other values. 
2. control of spontaneous proliferation: to determine the proliferation degree 
of non-treated cells. 18 hours before the end of the incubation BrdU was 
added to the cells.  
During this labelling period, the pyrimidine analogue BrdU was incorporated 
in place of thymidine into the DNA of proliferating cells. After removing the 
culture medium the cells were fixed and the DNA was denaturated by adding 
FixDenat for 30 minutes at room temperature. This step was essential to 
improve the accessibility of the incorporated BrdU for detection by the 
antibody. The anti-BrdU-POD was added to cells for 90 minutes at room 
temperature. It bound to the BrdU incorporated in newly synthesized 
endothelial cellular DNA. The immune complexes were detected by the 
subsequent substrate (TMB) reaction. The reaction product was quantified by 
measuring the absorbance at the respective wavelength using Microplate 
Autoreader at 405nm, reference wavelength 490nm. 
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3.2. Animal Models 
 
    3.2.1.   Sponge implantation for granuloma induction in rats 
Male Wistar rats (Harlan, Italy), weighing 200–220 g, were used in all 
experiments. Animals were provided with food and water ad libitum. The light 
cycle was automatically controlled (on 07 hrs 00 min.; off 19 hrs 00 min.) and 
the room temperature thermostatically regulated to 22 ± 1°C with 60 ± 5% 
humidity. Prior to the experiments, animals were housed in these conditions 
for 3–4 days to become acclimatized. Sponges were implanted as previously 
described by Iuvone et al., 1999. Briefly, two polyether sponges (0.5; 1.5; 2.0 
cm) weighing 0.035 ± 0.002 g were implanted subcutaneously on the back of 
rats (n = 12–18 for each group) under general anaesthesia with 
ketamin/xylazin 5 mg/mL. Sponges and surgery tools were sterilized by 
autoclaving for 20 min at 120°C. λ-carrageenin (1% w/v) (Sigma) was 
dissolved in pyrogen-free saline and injected into each sponge in presence or 
absence of 100 µL of PEA solution (200, 400, 800 µg/mL) in final volume of 
0.5 ml/sponge. Ninety-six hours after sponge implant, rats were sacrificed in 
atmosphere of CO2. The granulomatous tissue around the sponge was 
dissected by using a surgical blade (Fig. 3.2.1.), weighted, quickly frozen in 
liquid nitrogen, and stored at -80°C. Animal care as well as all experiments 
were in accordance with European Community Council Directive 86/609/EEC 
and efforts were made to minimize animal suffering and to reduce the 
number of animals used. 
 
       A)                                                             B) 
 
Figure 3.2.1.: Evaluation of (A) granuloma formation 96 hours after sponge implant and (B)    
after explant. 
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3.2.2.     Induction of Contact Allergic Dermatitis in mice 
Eight- to ten-week-old female C57BL/6J mice (Fig. 3.1.4.) were obtained 
from Harlan. Animal experiments were approved by the University of Naples, 
Federico II. The institutional and national guidelines for the care and use of 
laboratory animals were followed. 
2,4-Dinitrofluorobenzene (DNFB) was diluted in acetone/olive oil (4:1) 
immediately before use. Mice were sensitized by painting 50 µL of 0.2% 
DNFB on the shaved abdomen on two consecutive days. Controls were 
treated with 50µL acetone/ olive oil. Ears of mice were painted with 10 µL of 
0.3% DNFB on day 5. Ear thickness was measured 24, 48 and 72 h after 
challenge using an engineers micrometer, and ear swelling was calculated in 
each mouse as the difference in ear thickness between the unchallenged and 
the challenged ear. Statistical significances were evaluated with the 
Wilcoxon– Mann–Whitney two-samples test. After the third challenge and 
sacrifice, the ears were removed and immediately immersed into liquid 
nitrogen, to be stored at -80° until extraction and purification of PEA. N = 9 
mice per group were used for these experiments. These mice were the same 
that had been used previously for AEA and 2-AG level determination (38). 
 
 
    Figure 3.2.2.: C57BL/6J mouse. 
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3.3.  Biochemical Evaluations 
 
3.3.1.    ELISA Assay 
For the quantitative determination of rat Vascular Endothelial Growth Factor 
(VEGF) concentrations in C6 stimulated cells media, Quantikine® Rat VEGF 
Immunoassay (R&D Systems, Minneapolis, MN) was used. This assay 
employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody pre-coated onto the microplate react with standard, 
control and samples pipetted into the wells and any VEGF present is bound 
to the immobilized antibody. After washing away the unbound substances an 
enzyme-linked polyclonal antibody is added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a substrate solution is added 
to the wells. The enzyme reaction yields a blue product that turns yellow 
when the Stop solution is added. The intensity of the colour measured is in 
proportion to the amount of VEGF bound in the initial step. The samples 
values are then read off the standard curve.  
C6 cells were seeded (6.25x104/cm2), in 24-well plates for 24 hours in DMEM 
medium supplemented with 5% FBS (PromoCell, Heidelberg, Germany). The 
medium was then replaced with DMEM 2.5% FBS (PromoCell, Heidelberg, 
Germany) in absence or in presence of Aβ1-42 1 µg/mL (Tocris, Ellisville, 
MO), PEA (10-8; 10-7; 10-6 M; Epitech Group, Italy) and the selective PPAR-
?antagonist GW6471 (2,5µM; 5µM; 10µM) (Tocris, Ellisville, MO) for 48 
hours. At the end of incubation media were collected into polypropylene 
tubes. Samples were stored at lower -20°C temperature until use. After 
adding 50µl of Assay Diluent RD1-41, 50µl of standards (composed of 
dilution of rat VEGF standard from 2000pg/ml to 31.2pg/ml), control (given 
with kit) and samples were added to the pre-coated plate. 
The plate was covered and incubated 2 hours at room temperature on a 
horizontal microplate shaker. Five washings were performed with 400µl 
Wash Buffer to ensure the removal of any unbound substances. 100µl of Rat 
VEGF Conjugate were added to each well and the plate was incubated for 1 
hour at room temperature on the shaker. Five washings were performed and 
100µl of Substrate Solution were added to each well. After 30 minutes of 
incubation at room temperature on the benchtop protected from light, 100µl 
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of Stop solution were added to each well, gently tapping the plate 
to ensure thorough mixing. The optical density of each well was determine 
within 30 minutes, using the Microplate Autoreader ELISA (BioRad) set to 
450 nm, reference wavelength 570nm. Standard curve and quantitative 
analysis were obtained using the specific Microplate Autoreader Software. 
 
3.3.2.     Nitrite Determination 
NO was measured as nitrite (NO-2, 106nmol) accumulated in the incubation 
medium after 48 hours on C6 cells and on HUVEC cells in C6 conditioned 
media. A spectrophotometric assay based on the Griess reaction was used 
(D’Acquisto et al., 2001). Briefly, Griess reagent (1% sulphanilamide, 0.1% 
naphthylethylenediamine in phosphoric acid) was added to an equal volume 
of cell culture supernatant and the absorbance at 550 nm was measured 
after 10 min using the Microplate Autoreader (BioRad). The nitrite 
concentration was determined by reference to a standard curve of sodium 
nitrite. 
 
 
3.3.3.     Evaluation of Haemoglobin content in granulomas 
The granulomatous tissue, i.e. the new formation tissue encapsulating the 
sponge, was collected and measured with a balance weighting min 0.02 to 
max 300 g (KERN EG300-EM) always by the same person who was blinded 
for the treatments. In some experiments, the granulomatous tissue was 
homogenized on ice with the Polytron PT300 tissue homogenizer in 1 ml 
PBS (4 ml each g of wet weight). 
Briefly, after centrifugation at 2500 g for 20 min at 4°C, the supernatants 
were further centrifuged at 5000 g for 30 min and haemoglobin concentration 
in the supernatant was determined spectrophotometrically at 450 nm 
performed with the haemoglobin assay kit (Sigma Diagnostic). The 
haemoglobin content was expressed as mg haemoglobin/g of wet weight. 
 
3.3.4.    Reverse Transcriptase-Protein Chain Reaction (RT-PCR) 
Cytosolic and nuclear extracts from granulomatous tissues were performed 
as previously described. 
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The Bio-Rad protein assay kit determined protein concentration. The mRNA 
level of rMCP-5 in granulomatous tissue was determined using the semi-
quantitative RT-PCR method. The PCR-primers were selected according to 
the rat rMCP-5 cDNA sequence (forward primer 5’-
TCCTGCAAACACTTCACCAG-3’, reverse primer 5’-
CGAGATCCAGAGTTAATTCT- 3’); and rat β-actin cDNA  (forward primer 5’-
GGCACCACACCTTCTACA-3’ nucleotide positions 330-348, and reverse 
primer 5’-CAGGAGGAGCAATGATCT -3’). 15ml aliquots of PCR products 
were electrophoretically fractionated through 1% agarose gel containing the 
fluorescent Vistra green dye (Amersham Pharmacia Biotech, GE Healthcare; 
Switzerland). Labeling intensity of the PCR product, which is linear to the 
amount of DNA, was quantified using the Molecular Imager FX and Quantity 
One software (Biorad, Milan, Italy). 
 
3.3.5.    Western Blot Analysis 
 Western blot analysis was performed on C6 cells, on rat granulomatous 
tissue and on mice ears extracts, treated as described previously. 
Depending upon the experiments, cells or tissues were mechanically lysed.  
 
Briefly, 24 hours after treatment, C6 harvested cells (1×106cells) were 
washed twice with ice-cold PBS, and then it was centrifuged at 180g for 10 
min at 4°C. The pellet was re-suspended in 50µl of ice-cold hypotonic lysis 
buffer and incubated on ice for additional 15 min. The total protein extract 
was obtained by centrifugation at 13,000g for 15 min at 4°C. 
Rat granulomatous tissue and mice ears, previously mechanically 
homogenised, were lysed and the total protein extract obtained as described 
for cells. 
Samples were subjected to SDS-polyacrylamide gel electrophoresis, and 
proteins were transferred onto nitrocellulose membrane and incubated with 
one of the following antibodies: mouse anti-VEGF (1:1000 v/v; Neomarkers, 
Fremont CA), mouse anti-S100B (1:250 v/v; Abcam, Cambridge, UK), mouse 
anti-iNOS (1:1000 v/v; Transduction, Cambridge, UK), mouse anti-TNF-? 
(1:250 v/v; Neomarkers, Fremont CA), mouse anti- MMP9  (1:100 v/v; 
Neomarkers, Fremont CA), mouse anti-MITF (1:1000 v/v; Lifespan 
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Biosciences, Seattle, WA), mouse anti-p-ERK (1:2000 v/v; 
CellSignalling, Beverly, MA), mouse anti-β actin (1:1000 v/v; Santacruz, CA) 
and mouse anti-tubulin (1:1000 v/v; Santacruz, CA). Appropriate peroxidase-
conjugated secondary antibodies (1:1000 v/v; Santacruz, CA) were used, 
and proteins were visualized using an enhanced chemiluminescence kit (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). Protein expression was 
quantified by densitometric analysis of the acquired images by ImageQuant 
(GE Healthcare), with a GS 700 imaging densitometer (Bio-Rad, Hercules, 
CA) and a computer program (Molecular Analyst; IBM, White Plains, NY) 
 
3.3.6.   Electrophoretic Mobility Shift Assay (EMSA) 
Double stranded oligonucleotides containing the MITF recognition sequence 
(5’-CCT AGA CAG ACA AAA CCT AGA CAA TCA CGT GGC TGG-3’) were 
endlabelled with 32P-γ-ATP. Nuclear extracts containing 5µg protein were 
incubated for 15 min with radiolabeled oligonucleotides (2.5-5.0 x 104 cpm) in 
20µl reaction buffer containing 2 µg poly dI-dC, 10 mM Tris-HCl (pH 7.5), 100 
mM NaCl, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol. The specificity of the 
DNA/protein binding was determined by competition reaction in which a 50-
fold molar excess of unlabeled wild 80 type, mutant or Sp-1 oligonucleotide 
was added to the binding reaction 15 min before addition of radiolabeled 
probe. In supershift assay, antibodies reactive to MITF proteins were added 
to the reaction mixture 15 min before the addition of radiolabeled probe. 
Nuclear protein-oligonucleotide complexes were resolved by electrophoresis 
on a 6% non-denaturing polyacrylamide gel in 1x TBE buffer at 150 V for 2 h 
at 4 °C. The gel was dried and auto-radiographed with intensifying screen at 
–80 °C for 20 h. Subsequently, the relative bands were quantified by 
densitometric scanning of the X-ray films with a GS-700 Imaging 
Densitometer (Bio-Rad, Milan, Italy) and a computer program (Molecular 
Analyst; IBM).were endlabelled with 32P-g-ATP (Amersham, Milan, Italy). 
 
 
3.3.7.   Immunoprecipitation Assay 
For immunoprecipitation assay, 1 mg of protein extracts was incubated with 
30 µl of protein A/G agarose beads coated with 5 µg of antibody against 
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MITF at 4 °C for 12 h. The beads were washed and boiled in the SDS 
sample buffer. The eluted proteins were loaded on 12% SDS-PAGE. The 
membranes were blocked in PBS, 0.2% Tween and 5% dry milk for 2 h, and 
then challenged with anti-phosphoserine (1:1000 v/v; Pierce, Rockford, 
Illinois). The proteins were visualized chemiluminescence detection reagents 
(Amersham, GE Healthcare; Switzerland) according to the manufacturer’s 
instructions in Image quant 800 apparatus. The protein bands were analysed 
by densitometric analysis with a GS-800 imaging densitometer.  
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3.4. Histological Investigations 
 
3.4.1.   Mast cell Counting  
After excision of the implant, the rat granulomatous tissue around the sponge 
and the excised ears of the mice were put in 10% formalin. Thin (0.5µm) 
paraffin sections were prepared and stained with toluidine blue according to 
Iuvone et al. (1999) and then processed for light microscopy examination. 
Mast cells were counted in five randomly selected sections using a x100 
objective lens, differentiating between deep blue (un-degranulated) and light 
blue (degranulated) MCs. 
 
 
3.4.2.   Blood Vessels Evaluation 
The granulomatous tissue around the sponges on the back of rats was 
collected and measured with a balance weighting min 0.02 - max 300 gr 
(KERN EG300-EM) always by the same person who was blinded for the 
treatments. In some experiments, the granulomatous tissue was fixed in 
formol-methanol (9:1, v/v) solution at 4°C for 24h. After dehydration in an 
ethanol series and infiltration with xylol paraffin-wax sections were cut at 4-6 
µm and stained with haematoxylin and eosin. A vessel counting was 
performed on five randomly selected sections using a 100X objective lens. 
 
 
3.4.3.   Small Calibre Vessels Evaluation 
Excised ears of the mice were put in 10% formalin. Thin (0.5µm) paraffin 
sections were prepared and stained with a specific trichrome staining.  
The final blood vessels staining is due to the combination of three different 
staining from different solutions: 
- Solution A, also called plasma stain, containing acid fuchsin, Xylidine 
Ponceau, glacial acetic acid, and distilled water.  
-  Solution B contains phosphomolybdic acid in distilled water. 
- Solution C, also called fibre stain, contains Light Green SF yellowish, or 
alternatively Fast Green FCF.  
 
  
	   M.	  Cipriano	   	  
	   	  
68 
 
3.5.  Statistical Analysis  
Results are expressed as the means ± S.E.M. of n experiments. Statistical 
significance was calculated by one-way analysis of variance (ANOVA) and 
Bonferroni-corrected P-value for multiple comparison tests. The level of 
statistically significant difference was defined as P<0.05.  
Linear associations between variables were assessed by the use of 
standard-least-square linear regression.  
Correlation coefficient (r) was presented as measure of linear association for 
regression relationship. 
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4. Results	  
 
4.1. Effect of PEA on angiogenesis during neurodegeneration 
 
4.1.1.   Effect of PEA on reactive gliosis in C6 cells stimulated with Aβ 
(1-42) for 48 hoursù 
After Aβ stimulation glial cells undergo to reactive gliosis characterized by an 
increase of cell functionality and the release of several pro-inflammatory 
mediators.  Therefore, in order to evaluate reactive gliosis, we measured 
those parameters. First of all, PEA effect on functionality of C6 stimulated 
cells has been evaluated through MTT assay.  
As shown in Fig. 4.1.1., C6 cell functionality was significantly (P<0.001) 
increased in cells treated with Aβ (1-42) (1µg/mL) in confront to control (un-
treated) cells. The functionality of Aβ (1-42) stimulated C6 cells was 
significantly decreased after the administration of PEA (10-8-10-6M), in a 
concentration-dependent manner. 
 
 
 
Figure 4.1.1.: Effect of PEA on functionality of Aβ-stimulated C6 cells. Results are 
expressed as mean ± SEM of 3 experiments.  ***p<0.001 vs. Control; °p < 0.05, °°p < 0.01 
vs. Aβ (1-42) 1µg/mL. 
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Besides, cell stimulation with Aβ (1-42) (1µg/mL) for 48 hours, caused a 
significant (P<0.001) increase of nitrite levels in confront to the control. 
Interestingly, the treatment with PEA (10-8; 10-7; 10-6M) significantly and in a 
concentration dependent manner reduced the nitrite production (Fig 4.1.2.). 
 
 
 
 
Figure 4.1.2.: Effect of PEA on nitrite production in Aβ-stimulated C6 cells. Nitrite 
production has been evaluated through Griess reaction. Results are expressed as mean ± 
SEM of 3 experiments.  ***P<0.001 vs. Control; ° p <0.05, °°°p < 0.001 vs. Aβ (1-42) 
1µg/mL. 
 
 
Since several data suggest that the effects of PEA in astroglial cells are 
mainly mediated by a PPAR-α receptor signalling, we used GW6471, the 
selective antagonist of PPAR-α.   
As shown in Fig. 4.1.3., GW6471 (2,5 µM, 5 µM and 10 µM), significantly 
(P<0.001) and in a concentration-dependent manner, reverted the effect of 
PEA (higher concentration of 10-6M) on nitrite production from Aβ-stimulated 
C6 cells, thus confirming PEA  agonistic activity on PPAR-α.  
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Figure 4.1.3.:  Effect of GW6471 in reverting PEA effect on nitrite production from Aβ-
stimulated C6 cells. Nitrite production has been evaluated through Griess reaction. Results 
are expressed as mean ± SEM of 3 experiments.  ***P<0.001 vs. Control; °°°p < 0.001 vs. 
Aβ (1-42) 1µg/mL; ###p < 0.001 vs. PEA 10-6M. 
 
 
 
Other pro-inflammatory markers, as S100β and iNOS, were evaluated in C6 
cells in order to estimate their expression consequent to Aβ insult.  
Western blot analysis showed that the expression of both S100β and iNOS 
protein were considerably increased in C6 cells stimulated with Aβ (1-42) 
(1µg/mL) for 48 hours. PEA (10-8-10-7-10-6M) treatment significantly (P<0.5; 
P<0.01; P<0.001,) and in a concentration dependent manner reduced the 
expressions of both S100β (Fig. 4.1.4. A) and iNOS (Fig. 4.1.4. B) in C6 
cells.  
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A)                                                                     B) 
 
Figure 4.1.4.: Effect of PEA on S100β (A) and iNOS (B) protein expressions in Aβ-
stimulated C6 cells. S100β (A) and iNOS (B) protein expressions have been evaluated 
through Western Blot analysis. β-actin protein expression is shown as control. Results are 
expressed as mean ± SEM of 3 experiments. ***P<0.001 vs. Control; ?p<0.05, °°p<0.01, 
°°°p<0.001 vs. Aβ 1µg/mL. 
 
 
4.1.2.   Effect of PEA on pro- angiogenic factors in C6 cells stimulated 
with Aβ (1-42) for 48 hours 
Next we were aimed to demonstrate that C6 cells, stimulated with Aβ (1-42) 
(1µg/mL) for 48 h, were also able to produce and release pro- angiogenic 
factors.  
Hence, Western Blot analysis and ELISA assay for VEGF, MMP-9 and TNF-
α have been performed on Aβ stimulated cells. 
 
As shown in Fig. 4.1.5., the expressions of VEGF (A), MMP-9 (B) and TNF-α 
(C) were significantly (P<0.001) increased by Aβ treatment in confront to 
control (un-treated) cells.  
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                   A) 
 
B)                                                               C) 
 
Figure 4.1.5.: Effect of PEA on pro- angiogenic factors protein expressions in Aβ-
stimulated C6 cells. PEA effect on pro- angiogenic (A) VEGF, (B) MMP-9 and (C) TNF-α 
protein expressions has been evaluated through Western Blot analysis. β-actin protein 
expression is shown as control. Results are expressed as mean ± SEM of 3 experiments.  
***P<0.001 vs. Control; ?p<0.05, °°p<0.01, °°°p<0.001 vs. Aβ 1µg/mL.  
  
  
 
Treatment with PEA (10-8; 10-7; 10-6M) of Aβ stimulated C6 cells strongly 
reduced the expression of VEGF, as well as MMP-9 and TNF-α, even if a 
good concentration-effect correlation was not always observed (Fig. 4.1.5. A; 
B; C). 
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In order to clarify whether PEA was able to reduce not only the expression 
but also the release of pro- angiogenic mediators from Aβ stimulated C6 
cells, ELISA assay of VEGF release, the most important pro- angiogenic 
factor, has been performed on supernatants of Aβ stimulated cells.  
 VEGF release from C6 cells was considerably increased in Aβ (1µg/mL) 
stimulated cells in respect to the un-treated cells, and significantly decreased 
by PEA (10-8; 10-7; 10-6M) treatment in a concentration dependent manner 
(Fig. 4.1.6.). 
 
 
Figure 4.1.6.:  Effect of PEA on VEGF release in Aβ-stimulated C6 cells. The evaluation of 
PEA effect on VEGF release has been performed through ELISA assay. Results are expressed 
as mean ± SEM of 3 experiments. ***P<0.001 vs. Control; ?p<0.05, °°p<0.01, °°°p<0.001 vs. 
Aβ 1µg/mL. 
 
In order to clarify whether the effect of PEA on pro- angiogenic mediator 
release was also related to a PPAR-α-mediated mechanism, we used the 
selective antagonist of PPAR-α, GW6471.  
As shown in Fig. 4.1.7., GW6471 (2,5 µM, 5 µM and 10 µM) was able to 
revert, in a concentration dependent manner, PEA (10-6M) effect in reducing 
VEGF release from Aβ-stimulated C6 cells. The treatment with GW6471 
alone had no effect on VEGF release. 
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Figure 4.1.7.:  Effect of GW6471 in reverting PEA effect on VEGF release from Aβ-
stimulated C6 cells. The evaluation of GW6471 on VEGF release has been made through 
ELISA assay. Results are expressed as mean ± SEM of 3 experiments.  ***P<0.001 vs. 
Control; °°°p < 0.001 vs. Aβ (1-42) 1µg/mL; ###p < 0.001 vs. PEA 10-6M. 
 
4.1.3.  Effect of PEA on proliferation of HUVEC, incubated with C6-
conditioned medium 
The obtained results, explaining the capability of astroglial cells in expressing 
and releasing pro- angiogenic factors, have been an encouraging starting 
point for the subsequent aim: to study the effects of pro- angiogenic factors 
released by C6 cells, stimulated with Aβ 1µg/mL and treated with different 
concentrations of PEA (10-8-10-6M), on endothelial cells, which are 
responsible of tube formation, after the binding of VEGF to their membrane 
receptor, VEGFR-2.  
To assess the effect of Aβ (1-42) 1µg/mL and PEA (10-8-10-6M) on 
endothelial proliferation, BrdU experiments were performed on HUVEC cells, 
previously incubated for 24 hours with C6 conditioned media. 
Interestingly, proliferation was significantly (P<0.001) increased in HUVEC 
cells treated with Aβ (1-42) C6-conditioned medium, while PEA was able to 
contrast this effect in a concentration dependent manner, with having no 
effect on HUVEC that were treated with PEA alone (Fig. 4.1.8.) 
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Figure 4.1.8.:  Effect of PEA on proliferation of HUVEC, incubated with C6-conditioned 
medium. The evaluation of PEA effect on proliferation of HUVEC incubated with C6-
conditioned media has been made through BrdU assay. Results are expressed as mean ± 
SEM of 3 experiments.  ***P<0.001 vs. Control; °°°p < 0.001 vs. Aβ (1-42) 1µg/mL.  
 
Finally, in order to confirm the agonistic effect of PEA on PPAR-α, BrdU 
experiments were newly performed on HUVEC cells, previously incubated for 
24 hours with C6-conditioned media containing also GW6471 treatment. 
GW6471 at the concentrations of 2,5 µM, 5 µM and 10 µM was able to revert, 
in a concentration dependent manner, PEA 10-6M activity, that significantly 
had reduced HUVEC proliferation consequent to the incubation with Aβ-
stimulated C6 cells media. The treatment with GW6471 alone did not 
influence HUVEC proliferation (Fig. 4.1.9.). 
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Figure 4.1.9.:  Effect of GW6471 in reverting PEA effect on proliferation of HUVEC, 
incubated with C6-conditioned medium cells. The evaluation of GW6471 on HUVEC 
proliferation has been performed through BrdU assay. Results are expressed as mean ± 
SEM of 3 experiments.  ***P<0.001 vs. DMEM; °°°p < 0.001 vs. Aβ (1-42) 1µg/mL; ###p < 
0.001 vs. PEA 10-6M. 
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4.2. Effect of PEA on angiogenesis during granuloma 
 
4.2.1. Effect of PEA on wet weight of granulomatous tissue and on the 
Haemoglobin content  
In order to evaluate the effect of PEA on angiogenesis in chronic 
inflammation, it has been used a model of granuloma, that is a chronic 
inflammatory disease actively sustained by mast cell involvement (Iuvone et 
al. 1999): MCs are activated and their degranulation produces the release of 
different mediators, among which pro- angiogenic factors.  
The first evaluation that has been performed is the effect of PEA on 
granulomatous tissue formation, evaluated as wet weight of tissues and on 
the Haemoglobin content. 
The implant of sponges soaked with λ-carrageenin 1µg/mL on the back of 
rats, for 96 hours, caused a substantial increase (P<0.001) of granulomatous 
tissue in confront to the un-treated animals, that was significantly reduced by 
PEA 200, 400, 800 µg/mL, administered at the moment of implantation (Fig. 
4.2.1. A). 
Moreover, PEA (200, 400, 800 µg/mL) significantly (P<0.001) and 
concentration-dependently reduced also Haemoglobin content in the tissue, 
in comparison to λ-carrageenin alone (37.4±1.72 mg Hb/g tissue; Fig. 4.2.1. 
B). 
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               A)                                                                     B) 
 
 
Figure 4.2.1.: Effect of PEA on angiogenesis evaluated as (A) wet weigh of 
granulomatous tissue and (B) Haemoglobin content of granulomas. Results are 
expressed as mean ± SEM of 3 experiments.  ***P<0.001 vs. Saline; ?p < 0.05, °°p < 0.01, 
°°°p < 0.001 vs. λ-carrageenin alone. 
 
 
 
  
4.2.2.   Effect of PEA on the expression of pro- angiogenic mediators in 
granulomatous tissue 
In order to evaluate if PEA action on granulomatous tissue was linked to its 
activity in modulating angiogenesis, protein expression assays have been 
performed. 
More specifically, the expressions of VEGF, most important pro- angiogenic 
protein, TNF-α a pro- angiogenic and pro-inflammatory mediator have been 
evaluated through Western Blot Assay.  
The expressions of VEGF and TNF-α in granuloma, both drastically 
increased by the treatment with λ-carrageenin in confront to the un-treated 
rats, were significantly (P<0.001) decreased after the administration of PEA 
200, 400, 800 µg/mL, in a dose-responding manner (Fig. 4.2.2. A;B). 
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    A)                                                                  B) 
 
 
 
Figure 4.2.2.: Effect of PEA on expressions of (A) VEGF and (B) TNF-α pro- angiogenic 
factors. PEA effect on pro- angiogenic (A) VEGF, (B) TNF-α protein expressions has been 
evaluated through Western Blot analysis. Tubulin expression is shown as control. Results are 
expressed as mean ± SEM of 3 experiments.  ***P<0.001 vs. Saline; ?p<0.05, °°p<0.01, 
°°°p<0.001 vs. λ-carrageenin alone. 
  
 
 
 
Starting to the assumption that, after the release of VEGF, angiogenetic process 
prosecutes with its binding to the endothelial cells receptors, an evaluation of the 
expression of CD31, marker of endothelial cells, has been performed. 
As expected, CD31 protein expression was significantly increased by the 
treatment with λ-carrageenin, in confront to the un-treated animals. PEA was 
able to drastically reduce the expression of CD31 (8.45±0.78 OD=mm2; Fig. 
4.2.3.). 
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Figure 4.2.3.: Effect of PEA on CD31 protein expression. PEA effect on CD31 protein 
expression has been evaluated through Western Blot analysis. Results are expressed as mean 
± SEM of 3 experiments. Tubulin expression is shown as control. ***P<0.001 vs. Saline; ?p < 
0.05, °°p < 0.01, °°°p < 0.001 vs. λ-carrageenin alone. 
 
  
 
4.2.3.  Effect of PEA on new vessel formation in granulomatous tissue 
As the treatment with of λ-carrageenin 1% was able to increase pro- 
angiogenic factors, granulomatous tissue wet weight and its content of 
haemoglobin, histological analysis to evaluate blood vessels have been 
performed. 
Fig. 4.2.4. shows granulomatous tissues stained with haematoxylin and 
eosin: in granulomas from λ-carrageenin-treated rats, it is evident the 
elevated number of small calibre vessels, as an indication of on-going 
formation vessels. Vessels number was drastically reduced after the 
treatment with PEA at the higher dose (800 µg/mL), in confirming its effect in 
obstructing angiogenic process.  
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Figure 4.2.4.: Effect of PEA on small calibre vessels in granulomatous tissue. 
Representative histological analysis of granulomatous tissues stained with haematoxylin and 
eosin. 
 
 
4.2.4.  Effect of PEA on mast cell number and degranulation in 
granulomatous tissue 
Previously, the role of mast cells in sustaining the process of granuloma 
formation has been perfectly clarified (Iuvone et al. 1999). In parallel, 
stimulation of MCs and their consequent degranulation produce the release 
of various mediators, i.e. pro- angiogenic factors. Therefore, in order to 
elucidate whether PEA modulation of pro- angiogenic factors expression in 
granulomatous tissue was due to an ALIA mechanism, the number and the 
degranulation of MCs have been evaluated. 
Histological analysis of granulomas, stained with Toluidine Blue, revealed 
that PEA treatment (800 µg/mL) modulates MCs activity, in reducing their 
total number (deep blue, un-degranulated) and their degranulation (light blue, 
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degranulated) in respect to the tissues from rats treated with λ-
carrageenin alone (Fig. 4.2.5.). 
 
 
Figure 4.2.5.: Effect of PEA on λ-carrageenin activated mast cell. Representative histological 
analysis of granulomatous tissues stained with toluidine blue. Results are expressed as mean ± 
SEM of 3 experiments.  *p < 0.05, ***p<0.001 vs. saline; °°°p < 0.001 vs. λ-carrageenin alone. 
 
 
 
4.2.5.   Effect of PEA on rMCP-5 transcription and expression in 
granulomatous tissue 
In order to investigate whether PEA was able to influence rMCP-5 behaviour, 
a specific mast cell chymase possessing pro- angiogenic properties, different 
analysis of the amount of rMCP-5 in λ-carrageenin-induced granulomatous 
tissue in the presence or absence of PEA have been performed.  
Co-injection of PEA (200, 400 and 800 µg/ml) caused a dose-dependent 
reduction of rMCP-5 mRNA levels in tissue homogenates compared to λ -
carrageenin 1% (Fig. 4.2.6. A).  
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The inhibition of rMCP-5 expression operated by PEA was also confirmed by 
Western Blot analysis, where chymase was dose-dependently reduced by 
PEA treatment compared to λ –carrageenin 1% (Fig. 4.2.6. B). 
 
 
                      A)                                                                  B) 
 
 
Figure 4.2.6.: Effect of PEA on rMCP5 transcription (A) and expression (B) induced by 
λ-carrageenin in granulomatous tissue. Representative Vistra green-stained agarose gel 
of RT-PCR products (A), and Western Blot product (B). Tubulin expression is shown as 
control. Results are expressed as mean ± SEM of 3 experiments. ***P<0.001 vs. Saline.; °p 
< 0.05, °°p < 0.01, °°°p < 0.001 vs. λ-carrageenin alone. 
 
 
 
4.2.6.   Effect of PEA on MITF protein expression in granulomatous 
tissue 
The evaluation of MITF protein expression has been performed in 
considering its activation mechanism. Since MITF is activated by 
phosphorylation, that brings its translocation into the nucleus, a double 
analysis has been performed, according to its phosphorylation.  
The total MITF protein expression was significantly decreased in λ-
carrageenin-induced granulomatous tissues at 96 hours, if compared to the 
control tissues (Fig. 4.2.7. A), as a proof of its activation by inflammatory 
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stimuli. PEA administration produced a significant restoring of 
MITF protein levels into the granulomatous tissue, as compared with λ -
carrageenin alone.  
 
 
In another set of experiments, MITF was specifically immune-precipitated 
from protein extracts of tissues. Figure 4.2.7.B shows a significant (P<0.001) 
increase (2.6 fold) of the amount of phosphorylated MITF in λ -carrageenin-
induced granulomatous tissue compared to the control tissues. On the 
contrary, PEA treatment caused a decrease in the levels of phosphorylated 
MITF, if compared to the effect of λ –carragenin treatment. 
 
A) B) 
 
 
Figure 4.2.7.: Effect of PEA on λ-carrageenin-induced total (A) and phosphorylated (B) 
MITF protein expression in granulomatous tissue. Representative Western blot analysis and 
relative densitometric analysis of MITF protein levels in sponges injected with saline, λ-
carrageenin (1% w:v), or λ-carrageenin in the presence of increasing amount of PEA (200, 400, 
800 mg/ml) . Tubulin expression is shown as control. Results are expressed as mean ± SEM of 3 
experiments. ***P<0.001 vs. Saline; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs. λ-carrageenin alone. 
 
 
 
  
	   M.	  Cipriano	   	  
	   	  
86 
 
4.2.7.   Effect of PEA on p-ERK protein expression in granulomatous 
tissue 
Starting from the assumption that the phosphorylation of MITF is a key-
regulator event for its activation, concurrent to the ERK-pathway activation, 
Western Blot for p-ERK has been performed. 
As a result, the expression of p-ERK, which was significantly (P<0.001) 
increased by the treatment of λ-carrageenin 1% in respect to the control, was 
drastically decreased after the administration of PEA (200, 400, 800 µg/mL), 
in a dose-responding manner (Fig. 4.2.8.). 
 
 
 
Figure 4.2.8.:  Effect of PEA on λ-carrageenin-induced p-ERK expression in granulomatous 
tissue. PEA effect on p-ERK protein expression has been evaluated through Western Blot 
analysis. Tubulin expression is shown as control. Results are expressed as mean ± SEM of 3 
experiments. ***P<0.001 vs. Saline; °p < 0.05, °°p < 0.01 vs. λ-carrageenin alone. 
 
 
 
4.2.8.   Effect of PEA on MITF/DNA binding activity in granulomatous 
tissue 
To detect MITF/DNA binding activity, nuclear extracts from granulomatous 
tissues were analysed by EMSA. A basal level of MITF/DNA binding activity 
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was detected in nuclear extracts from tissues of saline-treated 
sponges evaluated 96 hours after implant. λ-Carrageenin treatment induced 
a marked increase of MITF/DNA binding activity that was significantly and 
dose-dependently reduced by the local administration of PEA (Fig 4.2.9. A). 
The composition of MITF/DNA binding complexes was determined by 
competition experiments. In the reaction of competition, the specificity of 
MITF/DNA binding complexes was evidenced by the complete displacement 
of MITF/DNA binding in the presence of a 50-fold molar excess of unlabeled 
MITF probe. In contrast, a 50-fold molar excess of unlabeled mutated MITF 
probe or Sp-1 had no effect on DNA/binding activity (Fig 4.2.9. B). 
 
   A)                                                                    B) 
 
Figure 4.2.9.: Effect of PEA on DNA binding activity and characterization of MITF 
complex in λ-carrageenin-induced granuloma. (A) EMSA showing the MITF binding 
activity in nuclear extracts from granulomatous tissues. (B) Characterization of the MITF/DNA 
complex. In competition reaction, nuclear extracts were incubated with radiolabeled MITF 
probe in absence or presence of: identical but unlabeled oligonucleotide (WT, 50x), mutated 
nonfunctional MITF probe (Mut. 50x) or unlabeled oligonucleotide containing the consensus 
sequence for Sp-1 (Sp-1, 50x). Data are from a single experiment representative of 3 separate 
assays. Densitometric data are expressed as mean±S.E.M. of 3 sponges from 3 rats. 
***p<0.001 vs. saline; °p<0.05, °°p<0.001 vs. λ-carragenin. 
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4.3. Effect of PEA on angiogenesis during Contact Allergic 
Dermatitis 
 
4.3.1.   Effect of PEA on mast cell number and degranulation in CAD- 
mice ears 
 The role of MCs in dermatitis has been well clarified, since several studies 
demonstrate their presence during the last phase of the disease.  
In order to investigate MC presence in CAD, and PEA effect in this model, 
histological analysis on mice ears, stained with Toluidine Blue, were 
performed. 
The staining reveals the effect of PEA treatment (5 mg/kg) in modulating 
MCs activity. 
Interestingly, as shown in Fig. 4.3.1., PEA did not reduce total number of 
MCs (deep blue, un-degranulated,).  
 
 
 
Figure 4.3.1.: Effect of PEA on number mast cells after DNFB treatment. Representative 
histological analysis of CAD mice ears stained with toluidine blue.  
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Fascinatingly, the effect of PEA was visible on MC activation (light blue, 
degranulated). 
In fact, histological analysis of ears explanted from mice treated i.p. with PEA 
5mg/kg, revealed its efficacy in reducing MC degranulation, in respect to the 
ears obtained from rats treated with DNFB alone (Fig. 4.3.2.) 
 
 
 
 
 
Figure 4.3.2.: Effect of PEA on degranulation of DNFB activated mast cells. Representative 
histological analysis of CAD mice ears stained with toluidine blue.  
 
 
 
4.3.2.   Effect of PEA on the expression of pro- angiogenic mediators in 
CAD- mice ears 
Starting from the assumption that several studies in DAC show the 
development of angiogenesis during the last phase of insult, and, since MC 
presence has been evaluated during the same phase, in order to evaluate 
PEA effect on angiogenesis related to MC activation, protein expression of 
pro- angiogenic mediators through Western Blot analysis has been 
performed on mice ears extracts. 
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Definitely, VEGF and TNF- α expressions were measured, not only as they 
are important pro- angiogenic factors, but also since they are critical 
mediators that are released during MC degranulation. 
 
As shown in Fig. 4.3.3.,TNF-α (A) and VEGF (B) protein expressions were 
significantly (P<0.001) increased in extracts of the ears obtained by DNFB 
0,3%-injured mice, as compared to the control. Interestingly, PEA 5mg/kg 
administration determined a significant (P<0.01) decrease of both TNF-α and 
VEGF protein expressions.  
  
      A)                                                             B) 
 
 
    Figure 4.3.3.: Effect of PEA on expressions of (A) TNF-α and (B) VEGF pro- 
angiogenic factors.   β-actin expression is shown as control. Results are expressed as 
mean ± SEM of 3  experiments.  ***P<0.001 vs. Control; °°p<0.01 vs. DNFB 0,3% alone. 
 
 
4.3.3.   Effect of PEA on new vessel formation in CAD- mice ears 
Last, in order to verify if the capability of PEA in modulating MCs 
degranulation and the consequent release of pro- angiogenic factors resulted 
also in a modulation of number of new vessel formation, histological analysis 
with a specific trichrome coloration has been performed. 
As shown in Fig. 4.3.4., the treatment with DNFB 0,3% strongly increased the 
number of new vessels in mice ears, in respect to the ears of the un-treated 
mice. This evaluation has been done according to the vessels calibre: small 
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calibre vessels, presumably meaning of angiogenesis, were 
increased by DNFB treatment. 
Moreover, the new vessel progression was located, basically, beside the 
external side of mice ears, where the DNFB injure had been executed.  
Interestingly, PEA treatment at the dose of 5 mg/kg, drastically reduced the 
effect of DNFB, in significantly decreasing the number of small calibre 
vessels.  
 
 
Figure 4.3.4.:  Effect of PEA on small calibre vessels during CAD. Representative histological 
analysis of mice ears tissues stained with tri-chromic staining. 
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5. Discussion 	  
	  
	  
The results of my Ph.D. study show, for the first time, the effect of 
ALIAmides in the control of pathological angiogenesis during inflammatory 
conditions, with main regard to Palmitoylethanolamide (PEA) which was able 
to reduce, both in vitro and in vivo, the angiogenic process occurring in 
astrogliosis, as well in granuloma formation and in contact allergic dermatitis.  
 
In order to investigate the mechanism of the anti- angiogenic effect of 
PEA, we focused our attention on two different cell types, strictly responsible 
for the starting and the progression of angiogenesis occurring in CNS and in 
periphery: the astroglial cells and the mast cells. Both these two cell-types 
are endowed with the entire machinery necessary to the ignition and 
progression of angiogenesis. In fact, several evidences show that, the 
activated astroglial cells during neurodegeneration, as well as hyper-
activated mast cells during inflammatory/allergic conditions, are able to 
release, together with pro-inflammatory mediators, a series of pro- 
angiogenic factors. Among them, mainly VEGF that, once released binds to 
its receptor, VEGFR-2, on the endothelial cells inducing their proliferation, 
and MMPs, which degrades extracellular matrix leading to new tube 
formation sprouting (Fioravanzo et al., 2010).  
In our experiments, administration of Aβ for 48 hours to rat astroglial cells, 
produced an increase of pro-inflammatory mediators, nitric oxide and S100β, 
as well of pro- angiogenic VEGF, TNF-α, MMP-9 protein expression. The 
increase of these mediators was strongly and significantly reduced by PEA 
treatment, in part confirming that PEA is able to manage the reactive gliosis 
after Aβ insult (Scuderi et al., 2011). Moreover, our results showed that the 
treatment with Aβ induced also the release of VEGF in medium thus 
suggesting that this diffusible pro- angiogenic mediator could stimulate the 
near vasculature to proliferate through the binding to its receptors on 
endothelial cells. Since PEA treatment significantly reduced, not only the 
expression of pro- angiogenic mediators, but also VEGF release than, 
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consequently, could prevent the VEGF-induced EC proliferation, in 
order to confirm this, we evaluated the HUVEC endothelial cell proliferation 
exposed to the conditioned medium deriving from Aβ-stimulated astroglial 
cells. As expected, the proliferation of HUVEC was increased by the 
treatment with conditioned medium from Aβ-stimulated cells, while PEA, 
given to astroglial cells, reduced HUVEC proliferation in view of the above 
reported reduction of pro- angiogenic factors release. Thus, the results here 
obtained support our idea that PEA could modulate angiogenesis occurring 
during neurodegeneration, since the in vitro model we used, is a reproducible 
and validate model to study angiogenesis associated to neurodegenerative 
process (Fioravanzo et al., 2010).  
As already stated, PEA mechanism of action still remains controversial, 
hence, in order to clarify its anti-proliferative effect on endothelial cells, we 
focused our attention on the reported effect of PEA on PPAR- α receptor.  
In fact, recent data have shown that PEA effect in ameliorating reactive 
gliosis is played through an agonism on PPAR- α receptor on astroglial cells 
(Sasso et al., 2011; Scuderi et al., 2011); in line with these evidences, we 
tested the selective PPAR- α antagonist, GW6471, which strongly reverted 
PEA action in our model, confirming that PEA anti-proliferative effect on 
endothelial cells is played by a PPAR- α-dependent mechanism on astroglial 
cells. 
In addition, part of my Ph.D. study was aimed to consolidate and expand 
previous evidences obtained by my group on the ability of PEA in controlling 
mast cell activation during chronic inflammation (De Filippis et al., 2011). 
Therefore, we evaluated the effect of PEA on angiogenesis occurring during 
in granuloma formation and allergic contact dermatitis (CAD), two 
experimental models where mast cells activation has been strongly validated  
(De Filippis et al., 2010; Petrosino et al., 2011), identifying in these cells the 
“orchestrator” of these pathologies. In particular, if the role of mast cell is 
important during all the phases of the granulomatous process, on the 
contrary during CAD, despite the strong involvement in the earlier phase of 
the disease of a different cell type, (keratinocyte), mast cell has been 
identified to contribute to the final phase (Iuvone al., 1999; Petrosino et al., 
2011). 
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Histological analysis from granulomatous tissues of rats treated with of λ-
carrageenin, as from the ears of the mice treated with DNFB, stained with 
Toluidine blue, evidenced an increasing of mast cell degranulation, in 
confront to the untreated animals. PEA administration, both in rats as in mice, 
significantly reduced MC degranulation, as showed by histological analysis. 
Moreover, PEA strongly reduced also the expression of pro- angiogenic 
mediators, VEGF, TNF-α, which were both increased in rats treated with λ-
carrageenin and in mice treated with DNFB, in respect to the untreated 
animals, thus suggesting that PEA could reduce new vessel formation in 
inflamed tissues by controlling mediators release from mast cell release. 
In order to confirm these, we performed a staining with haematoxylin/eosin of 
histologic sections of rats’ granulomas and mice’s ears to evidence the small 
vessel formation index of angiogenesis. Here, we evidenced a significant 
increase of the number of small calibre vessels in the rats’ granulomas 
treated with λ-carrageenin, as in the mice’s ears treated with DNFB, in 
respect to the untreated animals. In particular, during CAD the increase in the 
number of small calibre vessels has been reported beside the external side 
of mice ears, where the insult of DNFB has been executed. Treatment with 
PEA during CAD resulted in a significant decrease of small calibre vessels 
number, confirming PEA ability to control new vessel formation.  
Furthermore, in order to clarify the molecular mechanism of action of PEA 
during chronic inflammation, we studied the involvement of the transcription 
factor MITF during granuloma, which regulates the transcription of several 
genes in mast cells, including that coding for rMCP-5 protein. We 
demonstrated that local administration of PEA was able to prevent MITF 
activation and in parallel to down-regulate rMCP-5 expression (mRNA and 
protein levels), in granulomatous tissue from λ -carrageenin-treated rats. 
These data are well in accordance to a previous study of my group, showing 
the key pro- angiogenic role played by rMCP-5 during granuloma formation in 
rats (Russo et al., 2005). In particular phosphorylation/de-phosphorylation is 
a key regulatory step in MITF activation, since three serine sites (Ser73, 
Ser298 and Ser409) for its phosphorylation have been reported (Wu et al., 
2000); the phosphorylation of these sites positively correlates with the up-
regulation of MITF transcriptional activity. To confirm the ability of PEA to 
  
	   M.	  Cipriano	   	  
	   	  
95 
prevent MITF activation, we measured the phosphorylate state of 
MITF: interestingly, granulomatous tissue from λ-carrageenin exhibited a 
decrease of the total amount of MITF and an increase of phosphorylated 
MITF protein levels. PEA treatment reversed these effects, restoring total 
MITF protein levels to those one of granulomatous tissues from saline 
sponges. Thus, it is plausible that PEA is able to avoid the phosphorylation of 
MITF and, consequently, its phosphorylation-directed proteolytic degradation. 
Therefore, we investigated the main phosphorylation pathways leading to 
MITF activation, the MAPK cascade, studying ERK signalling. The 
phosphorylation of ERK is one of the key- events for the switch of the inactive 
state to the active form of several pro-inflammatory cascades. Our data 
evidenced that PEA reduced the amount of phosphorylated ERK, the activate 
form of this kinase. Interestingly, these data are in agreement with previous 
results demonstrating that PEA is able to control the activation fate of pro-
inflammatory cascades ending to the activation of important transcription 
factors, as AP-1 and NF-κB (D’Agostino et al., 2009). 
In conclusion, the present thesis show the strong effect of ALIAmide in 
controlling pathological angiogenesis which accompanies chronic 
inflammatory states both at central levels and in periphery through the 
modulation of two different cell types, astroglial cells and mast cells. Although 
these two cell types are completely different in function and in anatomic 
localisation, however are both of critical importances in the control of 
angiogenic process by the ability to undergo to activation and to release a 
plethora of both inflammatory and pro- angiogenic mediators that exacerbate 
the damage. The results here shown demonstrate, for the first time the 
capability of Palmitoylethanolamide in counteract the negative side of 
angiogenesis, acting as a pleiotropic molecule of a broad spectrum of 
activity.  
For this reason, it is conceivable to hypothesize the usage of PEA to prevent 
the chronicity of diseases during which angiogenesis plays the strong role in 
getting them worse and, in particular, in all those inflammatory conditions 
linked to astroglial cell hyperactivation and mast cell activation. 
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